"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_institute","contact_address","contact_city","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","disease status:ch1","pathological grade:ch1","pathological tstage:ch1","Sex:ch1","tissue:ch1"
"GSM3106847","Bladder Cancer [BL0001]","GSM3106847","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106847/suppl/GSM3106847_SH63Q63_Cell4.txt.gz","2565","59","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106848","Bladder Cancer [BL0003]","GSM3106848","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 77","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106848/suppl/GSM3106848_SH63W01_Cell2.txt.gz","2565","77","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106849","Bladder Cancer [BL0004]","GSM3106849","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106849/suppl/GSM3106849_SH63W01_Cell3.txt.gz","2565","50","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106850","Bladder Cancer [BL0007]","GSM3106850","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106850/suppl/GSM3106850_SH63W02_Cell2.txt.gz","2565","76","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106851","Bladder Cancer [BL0008]","GSM3106851","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106851/suppl/GSM3106851_SH63W02_Cell3.txt.gz","2565","81","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106852","Bladder Cancer [BL0009]","GSM3106852","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 54","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106852/suppl/GSM3106852_SH63W02_Cell4.txt.gz","2565","54","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106853","Bladder Cancer [BL0011]","GSM3106853","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106853/suppl/GSM3106853_SH63W03_Cell2.txt.gz","2565","74","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106854","Bladder Cancer [BL0012]","GSM3106854","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106854/suppl/GSM3106854_SH63W03_Cell3.txt.gz","2565","76","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106855","Bladder Cancer [BL0013]","GSM3106855","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106855/suppl/GSM3106855_SH63W03_Cell4.txt.gz","2565","58","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106856","Bladder Cancer [BL0014]","GSM3106856","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106856/suppl/GSM3106856_SH63W06_Cell1.txt.gz","2565","65","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106857","Bladder Cancer [BL0017]","GSM3106857","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106857/suppl/GSM3106857_SH63W06_Cell4.txt.gz","2565","71","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106858","Bladder Cancer [BL0018]","GSM3106858","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106858/suppl/GSM3106858_SH63W07_Cell1.txt.gz","2565","66","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106859","Bladder Cancer [BL0019]","GSM3106859","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106859/suppl/GSM3106859_SH63W07_Cell2.txt.gz","2565","77","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106860","Bladder Cancer [BL0020]","GSM3106860","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106860/suppl/GSM3106860_SH63H12_Cell4.txt.gz","2565","80","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106861","Bladder Cancer [BL0022]","GSM3106861","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106861/suppl/GSM3106861_SH63W08_Cell1.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106862","Bladder Cancer [BL0023]","GSM3106862","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106862/suppl/GSM3106862_SH63W08_Cell2.txt.gz","2565","81","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106863","Bladder Cancer [BL0024]","GSM3106863","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106863/suppl/GSM3106863_SH63W08_Cell3.txt.gz","2565","68","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106864","Bladder Cancer [BL0028]","GSM3106864","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106864/suppl/GSM3106864_SH63W09_Cell3.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106865","Bladder Cancer [BL0029]","GSM3106865","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106865/suppl/GSM3106865_SH63W09_Cell4.txt.gz","2565","81","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106866","Bladder Cancer [BL0030]","GSM3106866","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106866/suppl/GSM3106866_SH63W11_Cell1.txt.gz","2565","66","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106867","Bladder Cancer [BL0031]","GSM3106867","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106867/suppl/GSM3106867_SH63W11_Cell2.txt.gz","2565","61","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106868","Bladder Cancer [BL0032]","GSM3106868","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 55","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106868/suppl/GSM3106868_SH63W11_Cell3.txt.gz","2565","55","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106869","Bladder Cancer [BL0033]","GSM3106869","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 69","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106869/suppl/GSM3106869_SH63W11_Cell4.txt.gz","2565","69","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106870","Bladder Cancer [BL0037]","GSM3106870","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 48","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106870/suppl/GSM3106870_SH63H13_Cell2.txt.gz","2565","48","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106871","Bladder Cancer [BL0038]","GSM3106871","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106871/suppl/GSM3106871_SH63W13_Cell1.txt.gz","2565","80","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106872","Bladder Cancer [BL0039]","GSM3106872","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 80","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106872/suppl/GSM3106872_SH63W13_Cell2.txt.gz","2565","80","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106873","Bladder Cancer [BL0040]","GSM3106873","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106873/suppl/GSM3106873_SH63W13_Cell3.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106874","Bladder Cancer [BL0041]","GSM3106874","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106874/suppl/GSM3106874_SH63W13_Cell4.txt.gz","2565","69","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106875","Bladder Cancer [BL0042]","GSM3106875","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106875/suppl/GSM3106875_SH63W14_Cell1.txt.gz","2565","72","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106876","Bladder Cancer [BL0046]","GSM3106876","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106876/suppl/GSM3106876_SH63W15_Cell1.txt.gz","2565","53","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106877","Bladder Cancer [BL0047]","GSM3106877","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106877/suppl/GSM3106877_SH63W15_Cell2.txt.gz","2565","68","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106878","Bladder Cancer [BL0048]","GSM3106878","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 86","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106878/suppl/GSM3106878_SH63W15_Cell3.txt.gz","2565","86","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106879","Bladder Cancer [BL0049]","GSM3106879","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106879/suppl/GSM3106879_SH63W15_Cell4.txt.gz","2565","71","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106880","Bladder Cancer [BL0050]","GSM3106880","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106880/suppl/GSM3106880_SH63W16_Cell1.txt.gz","2565","67","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106881","Bladder Cancer [BL0051]","GSM3106881","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106881/suppl/GSM3106881_SH63W16_Cell2.txt.gz","2565","60","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106882","Bladder Cancer [BL0052]","GSM3106882","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106882/suppl/GSM3106882_SH63W16_Cell3.txt.gz","2565","67","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106883","Bladder Cancer [BL0053]","GSM3106883","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106883/suppl/GSM3106883_SH63W16_Cell4.txt.gz","2565","72","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106884","Bladder Cancer [BL0055]","GSM3106884","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 79","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106884/suppl/GSM3106884_SH63W18_Cell2.txt.gz","2565","79","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106885","Bladder Cancer [BL0056]","GSM3106885","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106885/suppl/GSM3106885_SH63W18_Cell3.txt.gz","2565","68","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106886","Bladder Cancer [BL0058]","GSM3106886","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106886/suppl/GSM3106886_SH63W19_Cell1.txt.gz","2565","77","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106887","Bladder Cancer [BL0060]","GSM3106887","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106887/suppl/GSM3106887_SH63W19_Cell3.txt.gz","2565","60","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3106888","Bladder Cancer [BL0061]","GSM3106888","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106888/suppl/GSM3106888_SH63W19_Cell4.txt.gz","2565","57","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106889","Bladder Cancer [BL0066]","GSM3106889","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106889/suppl/GSM3106889_SH63W22_Cell1.txt.gz","2565","65","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106890","Bladder Cancer [BL0067]","GSM3106890","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106890/suppl/GSM3106890_SH63W22_Cell2.txt.gz","2565","76","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106891","Bladder Cancer [BL0068]","GSM3106891","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 48","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106891/suppl/GSM3106891_SH63W22_Cell3.txt.gz","2565","48","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106892","Bladder Cancer [BL0070]","GSM3106892","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106892/suppl/GSM3106892_SH63W23_Cell1.txt.gz","2565","66","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106893","Bladder Cancer [BL0071]","GSM3106893","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 82","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106893/suppl/GSM3106893_SH63W23_Cell2.txt.gz","2565","82","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3106894","Bladder Cancer [BL0072]","GSM3106894","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106894/suppl/GSM3106894_SH63W23_Cell3.txt.gz","2565","68","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106895","Bladder Cancer [BL0074]","GSM3106895","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106895/suppl/GSM3106895_SH63W25_Cell1.txt.gz","2565","67","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106896","Bladder Cancer [BL0075]","GSM3106896","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 41","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106896/suppl/GSM3106896_SH63W25_Cell2.txt.gz","2565","41","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106897","Bladder Cancer [BL0076]","GSM3106897","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106897/suppl/GSM3106897_SH63W25_Cell3.txt.gz","2565","60","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106898","Bladder Cancer [BL0077]","GSM3106898","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106898/suppl/GSM3106898_SH63W25_Cell4.txt.gz","2565","78","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106899","Bladder Cancer [BL0078]","GSM3106899","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106899/suppl/GSM3106899_SH63W26_Cell1.txt.gz","2565","81","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106900","Bladder Cancer [BL0080]","GSM3106900","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 79","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106900/suppl/GSM3106900_SH63W26_Cell3.txt.gz","2565","79","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106901","Bladder Cancer [BL0082]","GSM3106901","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106901/suppl/GSM3106901_SH63W27_Cell1.txt.gz","2565","74","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106902","Bladder Cancer [BL0083]","GSM3106902","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106902/suppl/GSM3106902_SH63W27_Cell2.txt.gz","2565","76","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106903","Bladder Cancer [BL0084]","GSM3106903","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106903/suppl/GSM3106903_SH63W27_Cell3.txt.gz","2565","67","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106904","Bladder Cancer [BL0085]","GSM3106904","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106904/suppl/GSM3106904_SH63W27_Cell4.txt.gz","2565","63","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106905","Bladder Cancer [BL0087]","GSM3106905","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106905/suppl/GSM3106905_SH63W28_Cell2.txt.gz","2565","60","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106906","Bladder Cancer [BL0088]","GSM3106906","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106906/suppl/GSM3106906_SH63W28_Cell3.txt.gz","2565","64","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106907","Bladder Cancer [BL0089]","GSM3106907","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106907/suppl/GSM3106907_SH63W28_Cell4.txt.gz","2565","71","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106908","Bladder Cancer [BL0090]","GSM3106908","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 54","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106908/suppl/GSM3106908_SH63W29_Cell1.txt.gz","2565","54","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106909","Bladder Cancer [BL0091]","GSM3106909","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106909/suppl/GSM3106909_SH63W29_Cell2.txt.gz","2565","69","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106910","Bladder Cancer [BL0092]","GSM3106910","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106910/suppl/GSM3106910_SH63W29_Cell3.txt.gz","2565","68","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106911","Bladder Cancer [BL0093]","GSM3106911","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106911/suppl/GSM3106911_SH63W29_Cell4.txt.gz","2565","82","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106912","Bladder Cancer [BL0094]","GSM3106912","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106912/suppl/GSM3106912_SH63W31_Cell1.txt.gz","2565","63","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106913","Bladder Cancer [BL0097]","GSM3106913","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 83","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106913/suppl/GSM3106913_SH63W31_Cell4.txt.gz","2565","83","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106914","Bladder Cancer [BL0098]","GSM3106914","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106914/suppl/GSM3106914_SH63W32_Cell1.txt.gz","2565","79","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106915","Bladder Cancer [BL0100]","GSM3106915","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106915/suppl/GSM3106915_SH63W32_Cell3.txt.gz","2565","73","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106916","Bladder Cancer [BL0102]","GSM3106916","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106916/suppl/GSM3106916_SH63W33_Cell1.txt.gz","2565","82","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106917","Bladder Cancer [BL0105]","GSM3106917","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 80","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106917/suppl/GSM3106917_SH63W33_Cell4.txt.gz","2565","80","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106918","Bladder Cancer [BL0106]","GSM3106918","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106918/suppl/GSM3106918_SH63W36_Cell1.txt.gz","2565","59","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106919","Bladder Cancer [BL0107]","GSM3106919","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106919/suppl/GSM3106919_SH63W36_Cell2.txt.gz","2565","74","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106920","Bladder Cancer [BL0109]","GSM3106920","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 50","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106920/suppl/GSM3106920_SH63W36_Cell4.txt.gz","2565","50","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3106921","Bladder Cancer [BL0111]","GSM3106921","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 39","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106921/suppl/GSM3106921_SH63W37_Cell2.txt.gz","2565","39","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106922","Bladder Cancer [BL0112]","GSM3106922","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106922/suppl/GSM3106922_SH63W37_Cell3.txt.gz","2565","70","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106923","Bladder Cancer [BL0114]","GSM3106923","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 35","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106923/suppl/GSM3106923_SH63W39_Cell1.txt.gz","2565","35","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106924","Bladder Cancer [BL0116]","GSM3106924","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106924/suppl/GSM3106924_SH63W39_Cell3.txt.gz","2565","84","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106925","Bladder Cancer [BL0118]","GSM3106925","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 44","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106925/suppl/GSM3106925_SH63W40_Cell1.txt.gz","2565","44","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106926","Bladder Cancer [BL0120]","GSM3106926","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106926/suppl/GSM3106926_SH63H14_Cell1.txt.gz","2565","68","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106927","Bladder Cancer [BL0121]","GSM3106927","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106927/suppl/GSM3106927_SH63H14_Cell2.txt.gz","2565","60","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106928","Bladder Cancer [BL0122]","GSM3106928","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 85","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106928/suppl/GSM3106928_SH63W41_Cell1.txt.gz","2565","85","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106929","Bladder Cancer [BL0123]","GSM3106929","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106929/suppl/GSM3106929_SH63W41_Cell2.txt.gz","2565","62","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106930","Bladder Cancer [BL0126]","GSM3106930","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106930/suppl/GSM3106930_SH63W42_Cell1.txt.gz","2565","62","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106931","Bladder Cancer [BL0127]","GSM3106931","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106931/suppl/GSM3106931_SH63H14_Cell4.txt.gz","2565","82","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106932","Bladder Cancer [BL0129]","GSM3106932","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 59","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106932/suppl/GSM3106932_SH63H15_Cell2.txt.gz","2565","59","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106933","Bladder Cancer [BL0130]","GSM3106933","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106933/suppl/GSM3106933_SH63W43_Cell1.txt.gz","2565","70","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106934","Bladder Cancer [BL0131]","GSM3106934","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106934/suppl/GSM3106934_SH63W43_Cell2.txt.gz","2565","53","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106935","Bladder Cancer [BL0132]","GSM3106935","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106935/suppl/GSM3106935_SH63W43_Cell3.txt.gz","2565","72","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106936","Bladder Cancer [BL0134]","GSM3106936","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106936/suppl/GSM3106936_SH63W44_Cell1.txt.gz","2565","56","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106937","Bladder Cancer [BL0136]","GSM3106937","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106937/suppl/GSM3106937_SH63W44_Cell3.txt.gz","2565","73","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106938","Bladder Cancer [BL0138]","GSM3106938","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106938/suppl/GSM3106938_SH63W46_Cell1.txt.gz","2565","42","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106939","Bladder Cancer [BL0139]","GSM3106939","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106939/suppl/GSM3106939_SH63W46_Cell2.txt.gz","2565","67","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106940","Bladder Cancer [BL0140]","GSM3106940","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 83","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106940/suppl/GSM3106940_SH63W46_Cell3.txt.gz","2565","83","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106941","Bladder Cancer [BL0141]","GSM3106941","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106941/suppl/GSM3106941_SH63H15_Cell3.txt.gz","2565","62","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106942","Bladder Cancer [BL0142]","GSM3106942","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106942/suppl/GSM3106942_SH63W47_Cell1.txt.gz","2565","58","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106943","Bladder Cancer [BL0143]","GSM3106943","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106943/suppl/GSM3106943_SH63W47_Cell2.txt.gz","2565","57","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106944","Bladder Cancer [BL0144]","GSM3106944","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106944/suppl/GSM3106944_SH63W47_Cell3.txt.gz","2565","56","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106945","Bladder Cancer [BL0145]","GSM3106945","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106945/suppl/GSM3106945_SH63H15_Cell4.txt.gz","2565","56","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106946","Bladder Cancer [BL0146]","GSM3106946","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106946/suppl/GSM3106946_SH63W48_Cell1.txt.gz","2565","66","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106947","Bladder Cancer [BL0147]","GSM3106947","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106947/suppl/GSM3106947_SH63W48_Cell2.txt.gz","2565","76","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106948","Bladder Cancer [BL0148]","GSM3106948","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106948/suppl/GSM3106948_SH63W48_Cell3.txt.gz","2565","76","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106949","Bladder Cancer [BL0149]","GSM3106949","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 87","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106949/suppl/GSM3106949_SH63W48_Cell4.txt.gz","2565","87","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106950","Bladder Cancer [BL0150]","GSM3106950","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106950/suppl/GSM3106950_SH63W49_Cell1.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106951","Bladder Cancer [BL0151]","GSM3106951","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106951/suppl/GSM3106951_SH63H16_Cell1.txt.gz","2565","56","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3106952","Bladder Cancer [BL0152]","GSM3106952","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106952/suppl/GSM3106952_SH63W49_Cell3.txt.gz","2565","66","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106953","Bladder Cancer [BL0153]","GSM3106953","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106953/suppl/GSM3106953_SH63W57_Cell1.txt.gz","2565","52","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106954","Bladder Cancer [BL0154]","GSM3106954","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106954/suppl/GSM3106954_SH63W57_Cell2.txt.gz","2565","67","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106955","Bladder Cancer [BL0155]","GSM3106955","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106955/suppl/GSM3106955_SH63W57_Cell3.txt.gz","2565","58","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106956","Bladder Cancer [BL0157]","GSM3106956","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 38","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106956/suppl/GSM3106956_SH63W58_Cell1.txt.gz","2565","38","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106957","Bladder Cancer [BL0158]","GSM3106957","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106957/suppl/GSM3106957_SH63W58_Cell2.txt.gz","2565","71","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106958","Bladder Cancer [BL0159]","GSM3106958","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106958/suppl/GSM3106958_SH63W58_Cell3.txt.gz","2565","69","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106959","Bladder Cancer [BL0160]","GSM3106959","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106959/suppl/GSM3106959_SH63H16_Cell3.txt.gz","2565","62","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106960","Bladder Cancer [BL0161]","GSM3106960","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 93","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106960/suppl/GSM3106960_SH63W59_Cell1.txt.gz","2565","93","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106961","Bladder Cancer [BL0162]","GSM3106961","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106961/suppl/GSM3106961_SH63W59_Cell2.txt.gz","2565","56","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106962","Bladder Cancer [BL0164]","GSM3106962","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106962/suppl/GSM3106962_SH63H16_Cell4.txt.gz","2565","77","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3106963","Bladder Cancer [BL0165]","GSM3106963","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106963/suppl/GSM3106963_SH63W61_Cell1.txt.gz","2565","66","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106964","Bladder Cancer [BL0167]","GSM3106964","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106964/suppl/GSM3106964_SH63W61_Cell3.txt.gz","2565","64","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106965","Bladder Cancer [BL0168]","GSM3106965","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106965/suppl/GSM3106965_SH63H18_Cell1.txt.gz","2565","68","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106966","Bladder Cancer [BL0169]","GSM3106966","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 85","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106966/suppl/GSM3106966_SH63W62_Cell1.txt.gz","2565","85","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106967","Bladder Cancer [BL0172]","GSM3106967","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106967/suppl/GSM3106967_SH63W62_Cell4.txt.gz","2565","75","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106968","Bladder Cancer [BL0174]","GSM3106968","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106968/suppl/GSM3106968_SH63W63_Cell2.txt.gz","2565","81","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106969","Bladder Cancer [BL0175]","GSM3106969","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106969/suppl/GSM3106969_SH63W63_Cell3.txt.gz","2565","66","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106970","Bladder Cancer [BL0176]","GSM3106970","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106970/suppl/GSM3106970_SH63W63_Cell4.txt.gz","2565","63","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106971","Bladder Cancer [BL0177]","GSM3106971","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106971/suppl/GSM3106971_SH63X01_Cell1.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106972","Bladder Cancer [BL0178]","GSM3106972","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106972/suppl/GSM3106972_SH63X01_Cell2.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106973","Bladder Cancer [BL0179]","GSM3106973","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106973/suppl/GSM3106973_SH63X01_Cell3.txt.gz","2565","61","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106974","Bladder Cancer [BL0180]","GSM3106974","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106974/suppl/GSM3106974_SH63X01_Cell4.txt.gz","2565","61","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106975","Bladder Cancer [BL0181]","GSM3106975","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106975/suppl/GSM3106975_SH63X04_Cell1.txt.gz","2565","70","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106976","Bladder Cancer [BL0184]","GSM3106976","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106976/suppl/GSM3106976_SH63H18_Cell2.txt.gz","2565","78","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106977","Bladder Cancer [BL0185]","GSM3106977","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106977/suppl/GSM3106977_SH63X05_Cell1.txt.gz","2565","71","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106978","Bladder Cancer [BL0186]","GSM3106978","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106978/suppl/GSM3106978_SH63X05_Cell2.txt.gz","2565","74","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106979","Bladder Cancer [BL0188]","GSM3106979","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106979/suppl/GSM3106979_SH63X05_Cell4.txt.gz","2565","56","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3106980","Bladder Cancer [BL0189]","GSM3106980","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 85","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106980/suppl/GSM3106980_SH63H18_Cell3.txt.gz","2565","85","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106981","Bladder Cancer [BL0190]","GSM3106981","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106981/suppl/GSM3106981_SH63X07_Cell2.txt.gz","2565","67","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106982","Bladder Cancer [BL0193]","GSM3106982","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106982/suppl/GSM3106982_SH63X08_Cell1.txt.gz","2565","62","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106983","Bladder Cancer [BL0194]","GSM3106983","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106983/suppl/GSM3106983_SH63X08_Cell2.txt.gz","2565","78","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3106984","Bladder Cancer [BL0195]","GSM3106984","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106984/suppl/GSM3106984_SH63X08_Cell3.txt.gz","2565","80","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106985","Bladder Cancer [BL0196]","GSM3106985","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106985/suppl/GSM3106985_SH63X08_Cell4.txt.gz","2565","64","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106986","Bladder Cancer [BL0197]","GSM3106986","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106986/suppl/GSM3106986_SH63X09_Cell1.txt.gz","2565","68","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106987","Bladder Cancer [BL0198]","GSM3106987","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106987/suppl/GSM3106987_SH63X09_Cell2.txt.gz","2565","63","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106988","Bladder Cancer [BL0199]","GSM3106988","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106988/suppl/GSM3106988_SH63X09_Cell3.txt.gz","2565","50","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106989","Bladder Cancer [BL0200]","GSM3106989","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106989/suppl/GSM3106989_SH63X09_Cell4.txt.gz","2565","63","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106990","Bladder Cancer [BL0201]","GSM3106990","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106990/suppl/GSM3106990_SH63X11_Cell1.txt.gz","2565","75","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106991","Bladder Cancer [BL0203]","GSM3106991","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 80","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106991/suppl/GSM3106991_SH63X11_Cell3.txt.gz","2565","80","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3106992","Bladder Cancer [BL0205]","GSM3106992","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106992/suppl/GSM3106992_SH63X12_Cell1.txt.gz","2565","69","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106993","Bladder Cancer [BL0206]","GSM3106993","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106993/suppl/GSM3106993_SH63X12_Cell2.txt.gz","2565","50","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106994","Bladder Cancer [BL0210]","GSM3106994","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 82","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106994/suppl/GSM3106994_SH63X13_Cell2.txt.gz","2565","82","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3106995","Bladder Cancer [BL0211]","GSM3106995","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106995/suppl/GSM3106995_SH63X13_Cell3.txt.gz","2565","75","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3106996","Bladder Cancer [BL0212]","GSM3106996","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological grade: high","","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106996/suppl/GSM3106996_SH63X13_Cell4.txt.gz","2565","63","Bladder Cancer","high",NA,"Male","Serum"
"GSM3106997","Bladder Cancer [BL0216]","GSM3106997","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106997/suppl/GSM3106997_SH63X14_Cell4.txt.gz","2565","64","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3106998","Bladder Cancer [BL0217]","GSM3106998","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106998/suppl/GSM3106998_SH63X15_Cell1.txt.gz","2565","63","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3106999","Bladder Cancer [BL0219]","GSM3106999","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 85","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3106nnn/GSM3106999/suppl/GSM3106999_SH63X15_Cell3.txt.gz","2565","85","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107000","Bladder Cancer [BL0220]","GSM3107000","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107000/suppl/GSM3107000_SH63X15_Cell4.txt.gz","2565","75","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107001","Bladder Cancer [BL0222]","GSM3107001","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107001/suppl/GSM3107001_SH63X16_Cell2.txt.gz","2565","68","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107002","Bladder Cancer [BL0223]","GSM3107002","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 55","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107002/suppl/GSM3107002_SH63X16_Cell3.txt.gz","2565","55","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107003","Bladder Cancer [BL0224]","GSM3107003","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107003/suppl/GSM3107003_SH63X16_Cell4.txt.gz","2565","60","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107004","Bladder Cancer [BL0225]","GSM3107004","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107004/suppl/GSM3107004_SH63X18_Cell1.txt.gz","2565","61","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107005","Bladder Cancer [BL0226]","GSM3107005","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107005/suppl/GSM3107005_SH63X18_Cell2.txt.gz","2565","67","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107006","Bladder Cancer [BL0227]","GSM3107006","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107006/suppl/GSM3107006_SH63X18_Cell3.txt.gz","2565","75","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107007","Bladder Cancer [BL0228]","GSM3107007","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107007/suppl/GSM3107007_SH63X18_Cell4.txt.gz","2565","65","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107008","Bladder Cancer [BL0231]","GSM3107008","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107008/suppl/GSM3107008_SH63X19_Cell3.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107009","Bladder Cancer [BL0232]","GSM3107009","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107009/suppl/GSM3107009_SH63X19_Cell4.txt.gz","2565","73","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107010","Bladder Cancer [BL0233]","GSM3107010","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107010/suppl/GSM3107010_SH63X20_Cell1.txt.gz","2565","50","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107011","Bladder Cancer [BL0234]","GSM3107011","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107011/suppl/GSM3107011_SH63X20_Cell2.txt.gz","2565","71","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107012","Bladder Cancer [BL0235]","GSM3107012","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107012/suppl/GSM3107012_SH63X20_Cell3.txt.gz","2565","60","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107013","Bladder Cancer [BL0236]","GSM3107013","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107013/suppl/GSM3107013_SH64R58_Cell3.txt.gz","2565","84","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107014","Bladder Cancer [BL0237]","GSM3107014","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107014/suppl/GSM3107014_SH63X23_Cell1.txt.gz","2565","63","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107015","Bladder Cancer [BL0238]","GSM3107015","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107015/suppl/GSM3107015_SH63X23_Cell2.txt.gz","2565","70","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107016","Bladder Cancer [BL0240]","GSM3107016","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107016/suppl/GSM3107016_SH64R58_Cell4.txt.gz","2565","70","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107017","Bladder Cancer [BL0241]","GSM3107017","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107017/suppl/GSM3107017_SH63X25_Cell1.txt.gz","2565","63","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107018","Bladder Cancer [BL0243]","GSM3107018","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107018/suppl/GSM3107018_SH63X25_Cell3.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107019","Bladder Cancer [BL0244]","GSM3107019","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107019/suppl/GSM3107019_SH64R59_Cell1.txt.gz","2565","64","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107020","Bladder Cancer [BL0245]","GSM3107020","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 47","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107020/suppl/GSM3107020_SH63X36_Cell1.txt.gz","2565","47","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107021","Bladder Cancer [BL0246]","GSM3107021","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107021/suppl/GSM3107021_SH63X36_Cell2.txt.gz","2565","69","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107022","Bladder Cancer [BL0248]","GSM3107022","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107022/suppl/GSM3107022_SH63X36_Cell4.txt.gz","2565","70","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107023","Bladder Cancer [BL0249]","GSM3107023","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107023/suppl/GSM3107023_SH63X39_Cell1.txt.gz","2565","75","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107024","Bladder Cancer [BL0250]","GSM3107024","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107024/suppl/GSM3107024_SH63X39_Cell2.txt.gz","2565","78","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107025","Bladder Cancer [BL0251]","GSM3107025","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107025/suppl/GSM3107025_SH63X39_Cell3.txt.gz","2565","84","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107026","Bladder Cancer [BL0252]","GSM3107026","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107026/suppl/GSM3107026_SH63X39_Cell4.txt.gz","2565","62","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107027","Bladder Cancer [BL0253]","GSM3107027","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107027/suppl/GSM3107027_SH63X40_Cell1.txt.gz","2565","60","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107028","Bladder Cancer [BL0255]","GSM3107028","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 87","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107028/suppl/GSM3107028_SH63X40_Cell3.txt.gz","2565","87","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107029","Bladder Cancer [BL0256]","GSM3107029","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107029/suppl/GSM3107029_SH63X40_Cell4.txt.gz","2565","64","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107030","Bladder Cancer [BL0257]","GSM3107030","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107030/suppl/GSM3107030_SH63X41_Cell1.txt.gz","2565","68","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107031","Bladder Cancer [BL0258]","GSM3107031","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107031/suppl/GSM3107031_SH63X41_Cell2.txt.gz","2565","66","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107032","Bladder Cancer [BL0259]","GSM3107032","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107032/suppl/GSM3107032_SH63X41_Cell3.txt.gz","2565","82","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107033","Bladder Cancer [BL0260]","GSM3107033","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 42","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107033/suppl/GSM3107033_SH63X41_Cell4.txt.gz","2565","42","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107034","Bladder Cancer [BL0261]","GSM3107034","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107034/suppl/GSM3107034_SH63X42_Cell1.txt.gz","2565","76","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107035","Bladder Cancer [BL0262]","GSM3107035","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107035/suppl/GSM3107035_SH63X42_Cell2.txt.gz","2565","60","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107036","Bladder Cancer [BL0263]","GSM3107036","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107036/suppl/GSM3107036_SH63X42_Cell3.txt.gz","2565","60","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107037","Bladder Cancer [BL0264]","GSM3107037","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107037/suppl/GSM3107037_SH63X42_Cell4.txt.gz","2565","68","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107038","Bladder Cancer [BL0265]","GSM3107038","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107038/suppl/GSM3107038_SH63X44_Cell1.txt.gz","2565","60","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107039","Bladder Cancer [BL0266]","GSM3107039","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 49","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107039/suppl/GSM3107039_SH63X44_Cell2.txt.gz","2565","49","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107040","Bladder Cancer [BL0267]","GSM3107040","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107040/suppl/GSM3107040_SH63X44_Cell3.txt.gz","2565","65","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107041","Bladder Cancer [BL0269]","GSM3107041","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological grade: high","","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107041/suppl/GSM3107041_SH63X46_Cell1.txt.gz","2565","63","Bladder Cancer","high",NA,"Male","Serum"
"GSM3107042","Bladder Cancer [BL0270]","GSM3107042","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107042/suppl/GSM3107042_SH63X46_Cell2.txt.gz","2565","70","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107043","Bladder Cancer [BL0271]","GSM3107043","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107043/suppl/GSM3107043_SH63X46_Cell3.txt.gz","2565","76","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107044","Bladder Cancer [BL0273]","GSM3107044","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107044/suppl/GSM3107044_SH63X47_Cell1.txt.gz","2565","76","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107045","Bladder Cancer [BL0274]","GSM3107045","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107045/suppl/GSM3107045_SH63X47_Cell2.txt.gz","2565","71","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107046","Bladder Cancer [BL0275]","GSM3107046","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107046/suppl/GSM3107046_SH63X47_Cell3.txt.gz","2565","78","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107047","Bladder Cancer [BL0276]","GSM3107047","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 55","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107047/suppl/GSM3107047_SH63X47_Cell4.txt.gz","2565","55","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107048","Bladder Cancer [BL0278]","GSM3107048","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 87","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107048/suppl/GSM3107048_SH63X48_Cell2.txt.gz","2565","87","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107049","Bladder Cancer [BL0279]","GSM3107049","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107049/suppl/GSM3107049_SH63X48_Cell3.txt.gz","2565","81","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107050","Bladder Cancer [BL0280]","GSM3107050","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107050/suppl/GSM3107050_SH63X48_Cell4.txt.gz","2565","74","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107051","Bladder Cancer [BL0282]","GSM3107051","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107051/suppl/GSM3107051_SH63X49_Cell2.txt.gz","2565","73","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107052","Bladder Cancer [BL0283]","GSM3107052","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107052/suppl/GSM3107052_SH63X49_Cell3.txt.gz","2565","80","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107053","Bladder Cancer [BL0285]","GSM3107053","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107053/suppl/GSM3107053_SH63X50_Cell1.txt.gz","2565","61","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107054","Bladder Cancer [BL0286]","GSM3107054","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107054/suppl/GSM3107054_SH63X50_Cell2.txt.gz","2565","60","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107055","Bladder Cancer [BL0287]","GSM3107055","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107055/suppl/GSM3107055_SH63X50_Cell3.txt.gz","2565","79","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107056","Bladder Cancer [BL0288]","GSM3107056","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 54","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107056/suppl/GSM3107056_SH63X50_Cell4.txt.gz","2565","54","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107057","Bladder Cancer [BL0290]","GSM3107057","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107057/suppl/GSM3107057_SH63X51_Cell2.txt.gz","2565","67","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107058","Bladder Cancer [BL0291]","GSM3107058","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107058/suppl/GSM3107058_SH63X51_Cell3.txt.gz","2565","78","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107059","Bladder Cancer [BL0292]","GSM3107059","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107059/suppl/GSM3107059_SH63X51_Cell4.txt.gz","2565","77","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107060","Bladder Cancer [BL0293]","GSM3107060","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 87","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107060/suppl/GSM3107060_SH63X52_Cell1.txt.gz","2565","87","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107061","Bladder Cancer [BL0294]","GSM3107061","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 83","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107061/suppl/GSM3107061_SH63X52_Cell2.txt.gz","2565","83","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107062","Bladder Cancer [BL0296]","GSM3107062","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107062/suppl/GSM3107062_SH63X52_Cell4.txt.gz","2565","57","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107063","Bladder Cancer [BL0298]","GSM3107063","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107063/suppl/GSM3107063_SH63X54_Cell2.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107064","Bladder Cancer [BL0299]","GSM3107064","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107064/suppl/GSM3107064_SH63X54_Cell3.txt.gz","2565","78","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107065","Bladder Cancer [BL0300]","GSM3107065","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107065/suppl/GSM3107065_SH63X54_Cell4.txt.gz","2565","51","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107066","Bladder Cancer [BL0301]","GSM3107066","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107066/suppl/GSM3107066_SH63X55_Cell1.txt.gz","2565","63","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107067","Bladder Cancer [BL0304]","GSM3107067","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107067/suppl/GSM3107067_SH63X55_Cell4.txt.gz","2565","71","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107068","Bladder Cancer [BL0307]","GSM3107068","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107068/suppl/GSM3107068_SH63X57_Cell3.txt.gz","2565","78","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107069","Bladder Cancer [BL0308]","GSM3107069","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 32","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107069/suppl/GSM3107069_SH63X57_Cell4.txt.gz","2565","32","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107070","Bladder Cancer [BL0309]","GSM3107070","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 72","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107070/suppl/GSM3107070_SH63X58_Cell1.txt.gz","2565","72","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107071","Bladder Cancer [BL0310]","GSM3107071","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107071/suppl/GSM3107071_SH63X58_Cell2.txt.gz","2565","70","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107072","Bladder Cancer [BL0311]","GSM3107072","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 90","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107072/suppl/GSM3107072_SH63X58_Cell3.txt.gz","2565","90","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107073","Bladder Cancer [BL0313]","GSM3107073","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 48","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107073/suppl/GSM3107073_SH64R59_Cell2.txt.gz","2565","48","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107074","Bladder Cancer [BL0314]","GSM3107074","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107074/suppl/GSM3107074_SH64R59_Cell3.txt.gz","2565","67","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107075","Bladder Cancer [BL0315]","GSM3107075","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107075/suppl/GSM3107075_SH64R59_Cell4.txt.gz","2565","69","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107076","Bladder Cancer [BL0317]","GSM3107076","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107076/suppl/GSM3107076_SH63Y21_Cell2.txt.gz","2565","71","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107077","Bladder Cancer [BL0318]","GSM3107077","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107077/suppl/GSM3107077_SH63Y21_Cell3.txt.gz","2565","68","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107078","Bladder Cancer [BL0319]","GSM3107078","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107078/suppl/GSM3107078_SH63Y21_Cell4.txt.gz","2565","59","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107079","Bladder Cancer [BL0320]","GSM3107079","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107079/suppl/GSM3107079_SH63Y22_Cell1.txt.gz","2565","68","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107080","Bladder Cancer [BL0322]","GSM3107080","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107080/suppl/GSM3107080_SH63Y22_Cell3.txt.gz","2565","75","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107081","Bladder Cancer [BL0323]","GSM3107081","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107081/suppl/GSM3107081_SH64R60_Cell2.txt.gz","2565","66","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107082","Bladder Cancer [BL0324]","GSM3107082","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107082/suppl/GSM3107082_SH63Y23_Cell1.txt.gz","2565","78","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107083","Bladder Cancer [BL0325]","GSM3107083","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107083/suppl/GSM3107083_SH63Y23_Cell2.txt.gz","2565","73","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107084","Bladder Cancer [BL0326]","GSM3107084","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107084/suppl/GSM3107084_SH63Y23_Cell3.txt.gz","2565","76","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107085","Bladder Cancer [BL0327]","GSM3107085","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107085/suppl/GSM3107085_SH63Y23_Cell4.txt.gz","2565","74","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107086","Bladder Cancer [BL0328]","GSM3107086","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107086/suppl/GSM3107086_SH64R60_Cell3.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107087","Bladder Cancer [BL0329]","GSM3107087","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 54","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107087/suppl/GSM3107087_SH63Y25_Cell2.txt.gz","2565","54","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107088","Bladder Cancer [BL0330]","GSM3107088","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107088/suppl/GSM3107088_SH63Y25_Cell3.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107089","Bladder Cancer [BL0331]","GSM3107089","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107089/suppl/GSM3107089_SH66225_Cell3.txt.gz","2565","69","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107090","Bladder Cancer [BL0332]","GSM3107090","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107090/suppl/GSM3107090_SH63Y26_Cell1.txt.gz","2565","69","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107091","Bladder Cancer [BL0333]","GSM3107091","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 89","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107091/suppl/GSM3107091_SH63Y26_Cell2.txt.gz","2565","89","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107092","Bladder Cancer [BL0335]","GSM3107092","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107092/suppl/GSM3107092_SH63Y26_Cell4.txt.gz","2565","73","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107093","Bladder Cancer [BL0336]","GSM3107093","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107093/suppl/GSM3107093_SH63Y27_Cell1.txt.gz","2565","74","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107094","Bladder Cancer [BL0337]","GSM3107094","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107094/suppl/GSM3107094_SH63Y27_Cell2.txt.gz","2565","63","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107095","Bladder Cancer [BL0339]","GSM3107095","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 57","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107095/suppl/GSM3107095_SH63Y27_Cell4.txt.gz","2565","57","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107096","Bladder Cancer [BL0340]","GSM3107096","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107096/suppl/GSM3107096_SH63Y28_Cell1.txt.gz","2565","70","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107097","Bladder Cancer [BL0343]","GSM3107097","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107097/suppl/GSM3107097_SH63Y28_Cell4.txt.gz","2565","68","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107098","Bladder Cancer [BL0344]","GSM3107098","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107098/suppl/GSM3107098_SH63Y29_Cell1.txt.gz","2565","62","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107099","Bladder Cancer [BL0346]","GSM3107099","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107099/suppl/GSM3107099_SH63Y29_Cell3.txt.gz","2565","73","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107100","Bladder Cancer [BL0348]","GSM3107100","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107100/suppl/GSM3107100_SH63Y30_Cell1.txt.gz","2565","71","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107101","Bladder Cancer [BL0349]","GSM3107101","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107101/suppl/GSM3107101_SH63Y30_Cell2.txt.gz","2565","84","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107102","Bladder Cancer [BL0350]","GSM3107102","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107102/suppl/GSM3107102_SH63Y30_Cell3.txt.gz","2565","77","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107103","Bladder Cancer [BL0351]","GSM3107103","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107103/suppl/GSM3107103_SH63Y30_Cell4.txt.gz","2565","70","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107104","Bladder Cancer [BL0353]","GSM3107104","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107104/suppl/GSM3107104_SH63Y31_Cell2.txt.gz","2565","76","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107105","Bladder Cancer [BL0355]","GSM3107105","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107105/suppl/GSM3107105_SH63Y31_Cell4.txt.gz","2565","76","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107106","Bladder Cancer [BL0356]","GSM3107106","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107106/suppl/GSM3107106_SH63Y32_Cell1.txt.gz","2565","78","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107107","Bladder Cancer [BL0359]","GSM3107107","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107107/suppl/GSM3107107_SH63Y32_Cell4.txt.gz","2565","70","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107108","Bladder Cancer [BL0360]","GSM3107108","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107108/suppl/GSM3107108_SH63Y33_Cell1.txt.gz","2565","84","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107109","Bladder Cancer [BL0361]","GSM3107109","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 40","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107109/suppl/GSM3107109_SH63Y33_Cell2.txt.gz","2565","40","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107110","Bladder Cancer [BL0362]","GSM3107110","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107110/suppl/GSM3107110_SH63Y33_Cell3.txt.gz","2565","67","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107111","Bladder Cancer [BL0364]","GSM3107111","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107111/suppl/GSM3107111_SH63Y34_Cell1.txt.gz","2565","78","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107112","Bladder Cancer [BL0365]","GSM3107112","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107112/suppl/GSM3107112_SH63Y34_Cell2.txt.gz","2565","81","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107113","Bladder Cancer [BL0366]","GSM3107113","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107113/suppl/GSM3107113_SH63Y34_Cell3.txt.gz","2565","73","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107114","Bladder Cancer [BL0367]","GSM3107114","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107114/suppl/GSM3107114_SH63Y34_Cell4.txt.gz","2565","72","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107115","Bladder Cancer [BL0368]","GSM3107115","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107115/suppl/GSM3107115_SH63Y35_Cell1.txt.gz","2565","62","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107116","Bladder Cancer [BL0373]","GSM3107116","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 39","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107116/suppl/GSM3107116_SH63Y37_Cell2.txt.gz","2565","39","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107117","Bladder Cancer [BL0374]","GSM3107117","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107117/suppl/GSM3107117_SH63Y37_Cell3.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107118","Bladder Cancer [BL0375]","GSM3107118","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107118/suppl/GSM3107118_SH63Y37_Cell4.txt.gz","2565","69","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107119","Bladder Cancer [BL0376]","GSM3107119","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 34","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107119/suppl/GSM3107119_SH66225_Cell4.txt.gz","2565","34","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107120","Bladder Cancer [BL0377]","GSM3107120","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107120/suppl/GSM3107120_SH63Y38_Cell2.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107121","Bladder Cancer [BL0378]","GSM3107121","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107121/suppl/GSM3107121_SH63Y38_Cell3.txt.gz","2565","60","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107122","Bladder Cancer [BL0379]","GSM3107122","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107122/suppl/GSM3107122_SH63Y38_Cell4.txt.gz","2565","76","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107123","Bladder Cancer [BL0380]","GSM3107123","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107123/suppl/GSM3107123_SH63Y39_Cell1.txt.gz","2565","72","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107124","Bladder Cancer [BL0381]","GSM3107124","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107124/suppl/GSM3107124_SH63Y39_Cell2.txt.gz","2565","60","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107125","Bladder Cancer [BL0382]","GSM3107125","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 48","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107125/suppl/GSM3107125_SH63Y39_Cell3.txt.gz","2565","48","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107126","Bladder Cancer [BL0383]","GSM3107126","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107126/suppl/GSM3107126_SH63Y39_Cell4.txt.gz","2565","68","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107127","Bladder Cancer [BL0384]","GSM3107127","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 47","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107127/suppl/GSM3107127_SH63Y41_Cell1.txt.gz","2565","47","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107128","Bladder Cancer [BL0385]","GSM3107128","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107128/suppl/GSM3107128_SH63Y41_Cell2.txt.gz","2565","74","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107129","Bladder Cancer [BL0386]","GSM3107129","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107129/suppl/GSM3107129_SH63Y41_Cell3.txt.gz","2565","74","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107130","Bladder Cancer [BL0387]","GSM3107130","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107130/suppl/GSM3107130_SH63Y41_Cell4.txt.gz","2565","69","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107131","Bladder Cancer [BL0388]","GSM3107131","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107131/suppl/GSM3107131_SH63Y43_Cell1.txt.gz","2565","72","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107132","Bladder Cancer [BL0389]","GSM3107132","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107132/suppl/GSM3107132_SH63Y43_Cell2.txt.gz","2565","72","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107133","Bladder Cancer [BL0390]","GSM3107133","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107133/suppl/GSM3107133_SH63Y43_Cell3.txt.gz","2565","60","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107134","Bladder Cancer [BL0391]","GSM3107134","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 54","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107134/suppl/GSM3107134_SH63Y43_Cell4.txt.gz","2565","54","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107135","Bladder Cancer [BL0392]","GSM3107135","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 54","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107135/suppl/GSM3107135_SH63Y44_Cell1.txt.gz","2565","54","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107136","Bladder Cancer [BL0394]","GSM3107136","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107136/suppl/GSM3107136_SH63Y44_Cell3.txt.gz","2565","69","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107137","Bladder Cancer [BL0396]","GSM3107137","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 54","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107137/suppl/GSM3107137_SH63Y45_Cell1.txt.gz","2565","54","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107138","Bladder Cancer [BL0398]","GSM3107138","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107138/suppl/GSM3107138_SH63Y45_Cell3.txt.gz","2565","65","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107139","Bladder Cancer [BL0399]","GSM3107139","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107139/suppl/GSM3107139_SH66226_Cell2.txt.gz","2565","61","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107140","Bladder Cancer [BL0400]","GSM3107140","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107140/suppl/GSM3107140_SH63Y46_Cell1.txt.gz","2565","57","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107141","Bladder Cancer [BL0401]","GSM3107141","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107141/suppl/GSM3107141_SH63Y46_Cell2.txt.gz","2565","75","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107142","Bladder Cancer [BL0402]","GSM3107142","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107142/suppl/GSM3107142_SH63Y46_Cell3.txt.gz","2565","58","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107143","Bladder Cancer [BL0404]","GSM3107143","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107143/suppl/GSM3107143_SH63Y47_Cell1.txt.gz","2565","76","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107144","Bladder Cancer [BL0406]","GSM3107144","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107144/suppl/GSM3107144_SH63Y47_Cell3.txt.gz","2565","66","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107145","Bladder Cancer [BL0407]","GSM3107145","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107145/suppl/GSM3107145_SH63Y47_Cell4.txt.gz","2565","74","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107146","Bladder Cancer [BL0408]","GSM3107146","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107146/suppl/GSM3107146_SH63828_Cell1.txt.gz","2565","70","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107147","Bladder Cancer [BL0409]","GSM3107147","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107147/suppl/GSM3107147_SH63828_Cell2.txt.gz","2565","76","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107148","Bladder Cancer [BL0410]","GSM3107148","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107148/suppl/GSM3107148_SH63828_Cell3.txt.gz","2565","51","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107149","Bladder Cancer [BL0411]","GSM3107149","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107149/suppl/GSM3107149_SH63828_Cell4.txt.gz","2565","79","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107150","Bladder Cancer [BL0413]","GSM3107150","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107150/suppl/GSM3107150_SH63H02_Cell2.txt.gz","2565","75","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107151","Bladder Cancer [BL0414]","GSM3107151","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107151/suppl/GSM3107151_SH63H02_Cell3.txt.gz","2565","76","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107152","Bladder Cancer [BL0415]","GSM3107152","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107152/suppl/GSM3107152_SH66227_Cell1.txt.gz","2565","56","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107153","Bladder Cancer [BL0416]","GSM3107153","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 48","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107153/suppl/GSM3107153_SH63H03_Cell1.txt.gz","2565","48","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107154","Bladder Cancer [BL0417]","GSM3107154","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107154/suppl/GSM3107154_SH63H03_Cell2.txt.gz","2565","70","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107155","Bladder Cancer [BL0418]","GSM3107155","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107155/suppl/GSM3107155_SH63H03_Cell3.txt.gz","2565","70","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107156","Bladder Cancer [BL0419]","GSM3107156","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107156/suppl/GSM3107156_SH66227_Cell2.txt.gz","2565","74","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107157","Bladder Cancer [BL0420]","GSM3107157","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107157/suppl/GSM3107157_SH63H04_Cell1.txt.gz","2565","69","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107158","Bladder Cancer [BL0422]","GSM3107158","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107158/suppl/GSM3107158_SH63H04_Cell3.txt.gz","2565","63","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107159","Bladder Cancer [BL0423]","GSM3107159","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107159/suppl/GSM3107159_SH66227_Cell3.txt.gz","2565","63","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107160","Bladder Cancer [BL0424]","GSM3107160","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107160/suppl/GSM3107160_SH63H05_Cell1.txt.gz","2565","50","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107161","Bladder Cancer [BL0425]","GSM3107161","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107161/suppl/GSM3107161_SH63H05_Cell2.txt.gz","2565","67","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107162","Bladder Cancer [BL0426]","GSM3107162","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 43","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107162/suppl/GSM3107162_SH63H05_Cell3.txt.gz","2565","43","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107163","Bladder Cancer [BL0428]","GSM3107163","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107163/suppl/GSM3107163_SH63H06_Cell1.txt.gz","2565","82","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107164","Bladder Cancer [BL0429]","GSM3107164","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 61","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107164/suppl/GSM3107164_SH63H06_Cell2.txt.gz","2565","61","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107165","Bladder Cancer [BL0431]","GSM3107165","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107165/suppl/GSM3107165_SH66228_Cell1.txt.gz","2565","66","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107166","Bladder Cancer [BL0432]","GSM3107166","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107166/suppl/GSM3107166_SH63H07_Cell1.txt.gz","2565","66","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107167","Bladder Cancer [BL0433]","GSM3107167","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107167/suppl/GSM3107167_SH63H07_Cell2.txt.gz","2565","66","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107168","Bladder Cancer [BL0434]","GSM3107168","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107168/suppl/GSM3107168_SH63H07_Cell3.txt.gz","2565","51","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107169","Bladder Cancer [BL0435]","GSM3107169","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107169/suppl/GSM3107169_SH66228_Cell2.txt.gz","2565","80","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107170","Bladder Cancer [BL0436]","GSM3107170","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107170/suppl/GSM3107170_SH63H08_Cell1.txt.gz","2565","68","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107171","Bladder Cancer [BL0437]","GSM3107171","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 55","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107171/suppl/GSM3107171_SH63H08_Cell2.txt.gz","2565","55","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107172","Bladder Cancer [BL0438]","GSM3107172","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107172/suppl/GSM3107172_SH63H08_Cell3.txt.gz","2565","68","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107173","Bladder Cancer [BL0440]","GSM3107173","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107173/suppl/GSM3107173_SH63H09_Cell1.txt.gz","2565","63","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107174","Bladder Cancer [BL0441]","GSM3107174","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107174/suppl/GSM3107174_SH63H09_Cell2.txt.gz","2565","58","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107175","Bladder Cancer [BL0442]","GSM3107175","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107175/suppl/GSM3107175_SH63H09_Cell3.txt.gz","2565","56","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107176","Bladder Cancer [BL0443]","GSM3107176","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 47","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107176/suppl/GSM3107176_SH63H09_Cell4.txt.gz","2565","47","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107177","Bladder Cancer [BL0445]","GSM3107177","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107177/suppl/GSM3107177_SH63H11_Cell2.txt.gz","2565","72","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107178","Bladder Cancer [BL0446]","GSM3107178","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107178/suppl/GSM3107178_SH63H11_Cell3.txt.gz","2565","60","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107179","Bladder Cancer [BL0448]","GSM3107179","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107179/suppl/GSM3107179_SH63H12_Cell1.txt.gz","2565","71","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107180","Bladder Cancer [BL0449]","GSM3107180","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107180/suppl/GSM3107180_SH63H12_Cell2.txt.gz","2565","64","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107181","Bladder Cancer [BL0450]","GSM3107181","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 90","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107181/suppl/GSM3107181_SH63H12_Cell3.txt.gz","2565","90","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107182","Bladder Cancer [BL0451]","GSM3107182","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107182/suppl/GSM3107182_SH66228_Cell4.txt.gz","2565","70","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107183","Bladder Cancer [BL0452]","GSM3107183","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107183/suppl/GSM3107183_SH63H19_Cell2.txt.gz","2565","52","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107184","Bladder Cancer [BL0454]","GSM3107184","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107184/suppl/GSM3107184_SH66229_Cell1.txt.gz","2565","72","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107185","Bladder Cancer [BL0455]","GSM3107185","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 46","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107185/suppl/GSM3107185_SH63H21_Cell1.txt.gz","2565","46","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107186","Bladder Cancer [BL0456]","GSM3107186","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107186/suppl/GSM3107186_SH63H21_Cell2.txt.gz","2565","77","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107187","Bladder Cancer [BL0457]","GSM3107187","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107187/suppl/GSM3107187_SH63H21_Cell3.txt.gz","2565","79","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107188","Bladder Cancer [BL0458]","GSM3107188","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107188/suppl/GSM3107188_SH66229_Cell2.txt.gz","2565","52","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107189","Bladder Cancer [BL0459]","GSM3107189","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107189/suppl/GSM3107189_SH63H22_Cell1.txt.gz","2565","75","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107190","Bladder Cancer [BL0460]","GSM3107190","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107190/suppl/GSM3107190_SH63H22_Cell2.txt.gz","2565","60","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107191","Bladder Cancer [BL0461]","GSM3107191","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 83","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107191/suppl/GSM3107191_SH63H22_Cell3.txt.gz","2565","83","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107192","Bladder Cancer [BL0463]","GSM3107192","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107192/suppl/GSM3107192_SH63H23_Cell1.txt.gz","2565","81","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107193","Bladder Cancer [BL0464]","GSM3107193","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107193/suppl/GSM3107193_SH63H23_Cell2.txt.gz","2565","78","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107194","Bladder Cancer [BL0465]","GSM3107194","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107194/suppl/GSM3107194_SH63H23_Cell3.txt.gz","2565","74","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107195","Bladder Cancer [BL0466]","GSM3107195","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 48","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107195/suppl/GSM3107195_SH66229_Cell4.txt.gz","2565","48","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107196","Bladder Cancer [BL0467]","GSM3107196","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107196/suppl/GSM3107196_SH66230_Cell1.txt.gz","2565","69","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107197","Bladder Cancer [BL0468]","GSM3107197","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107197/suppl/GSM3107197_SH63H24_Cell2.txt.gz","2565","70","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107198","Bladder Cancer [BL0470]","GSM3107198","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107198/suppl/GSM3107198_SH63H24_Cell4.txt.gz","2565","65","Bladder Cancer","high",">=pT2","Female","Serum"
"GSM3107199","Bladder Cancer [BL0471]","GSM3107199","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107199/suppl/GSM3107199_SH63H25_Cell1.txt.gz","2565","77","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107200","Bladder Cancer [BL0473]","GSM3107200","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107200/suppl/GSM3107200_SH63H25_Cell3.txt.gz","2565","68","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107201","Bladder Cancer [BL0474]","GSM3107201","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107201/suppl/GSM3107201_SH66230_Cell2.txt.gz","2565","81","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107202","Bladder Cancer [BL0475]","GSM3107202","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107202/suppl/GSM3107202_SH63H26_Cell1.txt.gz","2565","71","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107203","Bladder Cancer [BL0476]","GSM3107203","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 86","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107203/suppl/GSM3107203_SH63H26_Cell2.txt.gz","2565","86","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107204","Bladder Cancer [BL0477]","GSM3107204","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107204/suppl/GSM3107204_SH63H26_Cell3.txt.gz","2565","77","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107205","Bladder Cancer [BL0478]","GSM3107205","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107205/suppl/GSM3107205_SH66230_Cell3.txt.gz","2565","60","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107206","Bladder Cancer [BL0479]","GSM3107206","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107206/suppl/GSM3107206_SH63H27_Cell1.txt.gz","2565","64","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107207","Bladder Cancer [BL0480]","GSM3107207","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107207/suppl/GSM3107207_SH63H27_Cell2.txt.gz","2565","66","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107208","Bladder Cancer [BL0481]","GSM3107208","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107208/suppl/GSM3107208_SH63H27_Cell3.txt.gz","2565","72","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107209","Bladder Cancer [BL0483]","GSM3107209","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107209/suppl/GSM3107209_SH63H28_Cell1.txt.gz","2565","67","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107210","Bladder Cancer [BL0484]","GSM3107210","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107210/suppl/GSM3107210_SH63H28_Cell2.txt.gz","2565","80","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107211","Bladder Cancer [BL0485]","GSM3107211","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107211/suppl/GSM3107211_SH63H28_Cell3.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107212","Bladder Cancer [BL0486]","GSM3107212","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107212/suppl/GSM3107212_SH66231_Cell1.txt.gz","2565","63","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107213","Bladder Cancer [BL0487]","GSM3107213","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107213/suppl/GSM3107213_SH63H29_Cell1.txt.gz","2565","64","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107214","Bladder Cancer [BL0488]","GSM3107214","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107214/suppl/GSM3107214_SH63H29_Cell2.txt.gz","2565","58","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107215","Bladder Cancer [BL0489]","GSM3107215","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107215/suppl/GSM3107215_SH66231_Cell2.txt.gz","2565","70","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107216","Bladder Cancer [BL0492]","GSM3107216","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107216/suppl/GSM3107216_SH63P30_Cell2.txt.gz","2565","66","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107217","Bladder Cancer [BL0493]","GSM3107217","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107217/suppl/GSM3107217_SH63P30_Cell3.txt.gz","2565","64","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107218","Bladder Cancer [BL0494]","GSM3107218","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107218/suppl/GSM3107218_SH63P30_Cell4.txt.gz","2565","65","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107219","Bladder Cancer [BL0495]","GSM3107219","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107219/suppl/GSM3107219_SH63X22_Cell1.txt.gz","2565","63","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107220","Bladder Cancer [BL0496]","GSM3107220","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107220/suppl/GSM3107220_SH63X22_Cell2.txt.gz","2565","73","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107221","Bladder Cancer [BL0497]","GSM3107221","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 72","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107221/suppl/GSM3107221_SH63X22_Cell3.txt.gz","2565","72","Bladder Cancer","low","<pT2","Female","Serum"
"GSM3107222","Bladder Cancer [BL0498]","GSM3107222","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107222/suppl/GSM3107222_SH63X22_Cell4.txt.gz","2565","71","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107223","Bladder Cancer [BL0499]","GSM3107223","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107223/suppl/GSM3107223_SH63X26_Cell1.txt.gz","2565","62","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107224","Bladder Cancer [BL0500]","GSM3107224","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107224/suppl/GSM3107224_SH63X26_Cell2.txt.gz","2565","80","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107225","Bladder Cancer [BL0501]","GSM3107225","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107225/suppl/GSM3107225_SH63X26_Cell3.txt.gz","2565","67","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107226","Bladder Cancer [BL0502]","GSM3107226","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107226/suppl/GSM3107226_SH63X26_Cell4.txt.gz","2565","67","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107227","Bladder Cancer [BL0503]","GSM3107227","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107227/suppl/GSM3107227_SH63X28_Cell1.txt.gz","2565","68","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107228","Bladder Cancer [BL0504]","GSM3107228","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107228/suppl/GSM3107228_SH63X28_Cell2.txt.gz","2565","71","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107229","Bladder Cancer [BL0505]","GSM3107229","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Bladder Cancer","pathological tstage: >=pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107229/suppl/GSM3107229_SH63X28_Cell3.txt.gz","2565","56","Bladder Cancer","high",">=pT2","Male","Serum"
"GSM3107230","Bladder Cancer [BL0506]","GSM3107230","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107230/suppl/GSM3107230_SH63X28_Cell4.txt.gz","2565","74","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107231","Bladder Cancer [BL0507]","GSM3107231","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107231/suppl/GSM3107231_SH63X29_Cell1.txt.gz","2565","81","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107232","Bladder Cancer [BL0508]","GSM3107232","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107232/suppl/GSM3107232_SH63X29_Cell2.txt.gz","2565","65","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107233","Bladder Cancer [BL0509]","GSM3107233","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: low","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107233/suppl/GSM3107233_SH66231_Cell4.txt.gz","2565","53","Bladder Cancer","low","<pT2","Male","Serum"
"GSM3107234","Bladder Cancer [BL0510]","GSM3107234","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107234/suppl/GSM3107234_SH63X29_Cell4.txt.gz","2565","61","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107235","Bladder Cancer [BL0511]","GSM3107235","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107235/suppl/GSM3107235_SH63X30_Cell1.txt.gz","2565","78","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107236","Bladder Cancer [BL0512]","GSM3107236","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 87","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107236/suppl/GSM3107236_SH63X30_Cell2.txt.gz","2565","87","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107237","Bladder Cancer [BL0513]","GSM3107237","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107237/suppl/GSM3107237_SH63X30_Cell3.txt.gz","2565","77","Bladder Cancer","high","<pT2","Male","Serum"
"GSM3107238","Bladder Cancer [BL0514]","GSM3107238","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Bladder Cancer","pathological tstage: <pT2","pathological grade: high","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107238/suppl/GSM3107238_SH63X30_Cell4.txt.gz","2565","71","Bladder Cancer","high","<pT2","Female","Serum"
"GSM3107239","Non-cancer control [XA0300]","GSM3107239","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107239/suppl/GSM3107239_SH4ZP56_Cell4.txt.gz","2565","42","Non-cancer control","NA","NA","Female","Serum"
"GSM3107240","Non-cancer control [XA0308]","GSM3107240","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 37","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107240/suppl/GSM3107240_SH4ZP58_Cell4.txt.gz","2565","37","Non-cancer control","NA","NA","Female","Serum"
"GSM3107241","Non-cancer control [XA0368]","GSM3107241","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 50","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107241/suppl/GSM3107241_SH4ZQ11_Cell4.txt.gz","2565","50","Non-cancer control","NA","NA","Female","Serum"
"GSM3107242","Non-cancer control [XA0509]","GSM3107242","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 55","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107242/suppl/GSM3107242_SH4ZR53_Cell4.txt.gz","2565","55","Non-cancer control","NA","NA","Female","Serum"
"GSM3107243","Non-cancer control [XA0523]","GSM3107243","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 49","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107243/suppl/GSM3107243_SH4ZR58_Cell2.txt.gz","2565","49","Non-cancer control","NA","NA","Female","Serum"
"GSM3107244","Non-cancer control [XA0593]","GSM3107244","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 52","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107244/suppl/GSM3107244_SH51D34_Cell4.txt.gz","2565","52","Non-cancer control","NA","NA","Female","Serum"
"GSM3107245","Non-cancer control [XA0646]","GSM3107245","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107245/suppl/GSM3107245_SH51E22_Cell4.txt.gz","2565","56","Non-cancer control","NA","NA","Female","Serum"
"GSM3107246","Non-cancer control [XA0670]","GSM3107246","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107246/suppl/GSM3107246_SH51E32_Cell4.txt.gz","2565","65","Non-cancer control","NA","NA","Female","Serum"
"GSM3107247","Non-cancer control [XA0687]","GSM3107247","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107247/suppl/GSM3107247_SH51E44_Cell1.txt.gz","2565","44","Non-cancer control","NA","NA","Female","Serum"
"GSM3107248","Non-cancer control [XA0730]","GSM3107248","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 69","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107248/suppl/GSM3107248_SH51E62_Cell4.txt.gz","2565","69","Non-cancer control","NA","NA","Female","Serum"
"GSM3107249","Non-cancer control [XA0833]","GSM3107249","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 51","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107249/suppl/GSM3107249_SH51K22_Cell3.txt.gz","2565","51","Non-cancer control","NA","NA","Female","Serum"
"GSM3107250","Non-cancer control [XA0986]","GSM3107250","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 52","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107250/suppl/GSM3107250_SH52611_Cell3.txt.gz","2565","52","Non-cancer control","NA","NA","Female","Serum"
"GSM3107251","Non-cancer control [XB0025]","GSM3107251","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 40","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107251/suppl/GSM3107251_SH52625_Cell4.txt.gz","2565","40","Non-cancer control","NA","NA","Male","Serum"
"GSM3107252","Non-cancer control [XB0325]","GSM3107252","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107252/suppl/GSM3107252_SH53B19_Cell4.txt.gz","2565","51","Non-cancer control","NA","NA","Male","Serum"
"GSM3107253","Non-cancer control [XB0392]","GSM3107253","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107253/suppl/GSM3107253_SH53R31_Cell2.txt.gz","2565","53","Non-cancer control","NA","NA","Male","Serum"
"GSM3107254","Non-cancer control [XB0282]","GSM3107254","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 46","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107254/suppl/GSM3107254_SH54107_Cell1.txt.gz","2565","46","Non-cancer control","NA","NA","Male","Serum"
"GSM3107255","Non-cancer control [XB0196]","GSM3107255","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107255/suppl/GSM3107255_SH54119_Cell2.txt.gz","2565","68","Non-cancer control","NA","NA","Male","Serum"
"GSM3107256","Non-cancer control [XB0459]","GSM3107256","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 43","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107256/suppl/GSM3107256_SH54803_Cell2.txt.gz","2565","43","Non-cancer control","NA","NA","Male","Serum"
"GSM3107257","Non-cancer control [XB0567]","GSM3107257","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107257/suppl/GSM3107257_SH54968_Cell2.txt.gz","2565","59","Non-cancer control","NA","NA","Male","Serum"
"GSM3107258","Non-cancer control [XB0614]","GSM3107258","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 44","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107258/suppl/GSM3107258_SH54E19_Cell1.txt.gz","2565","44","Non-cancer control","NA","NA","Male","Serum"
"GSM3107259","Non-cancer control [XB0706]","GSM3107259","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 55","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107259/suppl/GSM3107259_SH55B44_Cell4.txt.gz","2565","55","Non-cancer control","NA","NA","Male","Serum"
"GSM3107260","Non-cancer control [XB0863]","GSM3107260","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107260/suppl/GSM3107260_SH55M05_Cell2.txt.gz","2565","53","Non-cancer control","NA","NA","Male","Serum"
"GSM3107261","Non-cancer control [XB0938]","GSM3107261","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 36","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107261/suppl/GSM3107261_SH55M49_Cell1.txt.gz","2565","36","Non-cancer control","NA","NA","Male","Serum"
"GSM3107262","Non-cancer control [XB0794]","GSM3107262","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107262/suppl/GSM3107262_SH56833_Cell4.txt.gz","2565","58","Non-cancer control","NA","NA","Male","Serum"
"GSM3107263","Non-cancer control [XA0044]","GSM3107263","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107263/suppl/GSM3107263_SH5XD39_Cell4.txt.gz","2565","44","Non-cancer control","NA","NA","Female","Serum"
"GSM3107264","Non-cancer control [M11101105]","GSM3107264","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 92","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107264/suppl/GSM3107264_SH63Z42_Cell1.txt.gz","2565","92","Non-cancer control","NA","NA","Female","Serum"
"GSM3107265","Non-cancer control [NB14091901]","GSM3107265","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107265/suppl/GSM3107265_SH64705_Cell3.txt.gz","2565","73","Non-cancer control","NA","NA","Female","Serum"
"GSM3107266","Non-cancer control [M11070402]","GSM3107266","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 89","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107266/suppl/GSM3107266_SH64L32_Cell1.txt.gz","2565","89","Non-cancer control","NA","NA","Female","Serum"
"GSM3107267","Non-cancer control [M10122802]","GSM3107267","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107267/suppl/GSM3107267_SH66E11_Cell4.txt.gz","2565","76","Non-cancer control","NA","NA","Female","Serum"
"GSM3107268","Non-cancer control [M10121601]","GSM3107268","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107268/suppl/GSM3107268_SH66E39_Cell1.txt.gz","2565","81","Non-cancer control","NA","NA","Male","Serum"
"GSM3107269","Non-cancer control [M11042602]","GSM3107269","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107269/suppl/GSM3107269_SH66F26_Cell1.txt.gz","2565","62","Non-cancer control","NA","NA","Male","Serum"
"GSM3107270","Non-cancer control [M11111103]","GSM3107270","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107270/suppl/GSM3107270_SH66M17_Cell4.txt.gz","2565","58","Non-cancer control","NA","NA","Female","Serum"
"GSM3107271","Non-cancer control [M11122103]","GSM3107271","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 53","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107271/suppl/GSM3107271_SH66M59_Cell1.txt.gz","2565","53","Non-cancer control","NA","NA","Female","Serum"
"GSM3107272","Non-cancer control [NB12041901]","GSM3107272","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 87","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107272/suppl/GSM3107272_SH66N57_Cell2.txt.gz","2565","87","Non-cancer control","NA","NA","Male","Serum"
"GSM3107273","Non-cancer control [NB12111401]","GSM3107273","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107273/suppl/GSM3107273_SH66X04_Cell3.txt.gz","2565","73","Non-cancer control","NA","NA","Male","Serum"
"GSM3107274","Non-cancer control [NB13041504]","GSM3107274","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107274/suppl/GSM3107274_SH67427_Cell1.txt.gz","2565","81","Non-cancer control","NA","NA","Male","Serum"
"GSM3107275","Non-cancer control [NB13052101]","GSM3107275","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107275/suppl/GSM3107275_SH67450_Cell3.txt.gz","2565","70","Non-cancer control","NA","NA","Male","Serum"
"GSM3107276","Non-cancer control [NB13053103]","GSM3107276","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 80","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107276/suppl/GSM3107276_SH67457_Cell3.txt.gz","2565","80","Non-cancer control","NA","NA","Female","Serum"
"GSM3107277","Non-cancer control [NB13062502]","GSM3107277","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107277/suppl/GSM3107277_SH68937_Cell1.txt.gz","2565","51","Non-cancer control","NA","NA","Male","Serum"
"GSM3107278","Non-cancer control [NB13101502]","GSM3107278","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107278/suppl/GSM3107278_SH69116_Cell1.txt.gz","2565","79","Non-cancer control","NA","NA","Male","Serum"
"GSM3107279","Non-cancer control [NB14030504]","GSM3107279","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 80","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107279/suppl/GSM3107279_SH69741_Cell3.txt.gz","2565","80","Non-cancer control","NA","NA","Female","Serum"
"GSM3107280","Non-cancer control [NB14071601]","GSM3107280","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107280/suppl/GSM3107280_SH69863_Cell2.txt.gz","2565","81","Non-cancer control","NA","NA","Female","Serum"
"GSM3107281","Non-cancer control [NB14110603]","GSM3107281","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 83","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107281/suppl/GSM3107281_SH69F13_Cell4.txt.gz","2565","83","Non-cancer control","NA","NA","Female","Serum"
"GSM3107282","Non-cancer control [CHC785]","GSM3107282","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 75","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107282/suppl/GSM3107282_SH69X47_Cell1.txt.gz","2565","75","Non-cancer control","NA","NA","Female","Serum"
"GSM3107283","Non-cancer control [NB15052601]","GSM3107283","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107283/suppl/GSM3107283_SH6XT35_Cell1.txt.gz","2565","81","Non-cancer control","NA","NA","Female","Serum"
"GSM3107284","Non-cancer control [NB15070702]","GSM3107284","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107284/suppl/GSM3107284_SH6Y227_Cell1.txt.gz","2565","74","Non-cancer control","NA","NA","Female","Serum"
"GSM3107285","Non-cancer control [NB15101502]","GSM3107285","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107285/suppl/GSM3107285_SH6Y906_Cell2.txt.gz","2565","81","Non-cancer control","NA","NA","Female","Serum"
"GSM3107286","Non-cancer control [NB15120103]","GSM3107286","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107286/suppl/GSM3107286_SH6Y950_Cell3.txt.gz","2565","78","Non-cancer control","NA","NA","Male","Serum"
"GSM3107287","Non-cancer control [NB15122204]","GSM3107287","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 85","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107287/suppl/GSM3107287_SH6YG31_Cell2.txt.gz","2565","85","Non-cancer control","NA","NA","Male","Serum"
"GSM3107288","Non-cancer control [NB15122506]","GSM3107288","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107288/suppl/GSM3107288_SH6YG37_Cell1.txt.gz","2565","73","Non-cancer control","NA","NA","Male","Serum"
"GSM3107289","Non-cancer control [CHC797]","GSM3107289","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107289/suppl/GSM3107289_SH6X346_Cell4.txt.gz","2565","67","Non-cancer control","NA","NA","Male","Serum"
"GSM3107290","Non-cancer control [M10121602]","GSM3107290","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 85","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107290/suppl/GSM3107290_SH66E42_Cell4.txt.gz","2565","85","Non-cancer control","NA","NA","Male","Serum"
"GSM3107291","Non-cancer control [M11012502]","GSM3107291","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107291/suppl/GSM3107291_SH66E14_Cell4.txt.gz","2565","76","Non-cancer control","NA","NA","Female","Serum"
"GSM3107292","Non-cancer control [M11061002]","GSM3107292","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107292/suppl/GSM3107292_SH64L42_Cell2.txt.gz","2565","75","Non-cancer control","NA","NA","Male","Serum"
"GSM3107293","Non-cancer control [M11091302]","GSM3107293","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 75","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107293/suppl/GSM3107293_SH66L54_Cell4.txt.gz","2565","75","Non-cancer control","NA","NA","Female","Serum"
"GSM3107294","Non-cancer control [M11110203]","GSM3107294","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107294/suppl/GSM3107294_SH63Z47_Cell1.txt.gz","2565","78","Non-cancer control","NA","NA","Female","Serum"
"GSM3107295","Non-cancer control [M11120803]","GSM3107295","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107295/suppl/GSM3107295_SH66M50_Cell2.txt.gz","2565","76","Non-cancer control","NA","NA","Male","Serum"
"GSM3107296","Non-cancer control [NB12022204]","GSM3107296","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107296/suppl/GSM3107296_SH66N28_Cell1.txt.gz","2565","78","Non-cancer control","NA","NA","Female","Serum"
"GSM3107297","Non-cancer control [NB12071901]","GSM3107297","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107297/suppl/GSM3107297_SH66P39_Cell3.txt.gz","2565","82","Non-cancer control","NA","NA","Male","Serum"
"GSM3107298","Non-cancer control [NB13032501]","GSM3107298","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 88","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107298/suppl/GSM3107298_SH66Y16_Cell4.txt.gz","2565","88","Non-cancer control","NA","NA","Female","Serum"
"GSM3107299","Non-cancer control [NB13050803]","GSM3107299","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107299/suppl/GSM3107299_SH67442_Cell1.txt.gz","2565","73","Non-cancer control","NA","NA","Female","Serum"
"GSM3107300","Non-cancer control [NB13052306]","GSM3107300","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 86","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107300/suppl/GSM3107300_SH67453_Cell2.txt.gz","2565","86","Non-cancer control","NA","NA","Male","Serum"
"GSM3107301","Non-cancer control [NB13061003]","GSM3107301","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 86","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107301/suppl/GSM3107301_SH67462_Cell1.txt.gz","2565","86","Non-cancer control","NA","NA","Male","Serum"
"GSM3107302","Non-cancer control [NB13080201]","GSM3107302","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 77","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107302/suppl/GSM3107302_SH68Z11_Cell4.txt.gz","2565","77","Non-cancer control","NA","NA","Female","Serum"
"GSM3107303","Non-cancer control [NB13120602]","GSM3107303","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107303/suppl/GSM3107303_SH69521_Cell3.txt.gz","2565","70","Non-cancer control","NA","NA","Male","Serum"
"GSM3107304","Non-cancer control [NB14031302]","GSM3107304","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 87","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107304/suppl/GSM3107304_SH69745_Cell2.txt.gz","2565","87","Non-cancer control","NA","NA","Female","Serum"
"GSM3107305","Non-cancer control [NB14081101]","GSM3107305","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107305/suppl/GSM3107305_SH69E22_Cell2.txt.gz","2565","80","Non-cancer control","NA","NA","Male","Serum"
"GSM3107306","Non-cancer control [NB14102003]","GSM3107306","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 83","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107306/suppl/GSM3107306_SH69F02_Cell1.txt.gz","2565","83","Non-cancer control","NA","NA","Female","Serum"
"GSM3107307","Non-cancer control [NB14121901]","GSM3107307","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 77","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107307/suppl/GSM3107307_SH69X09_Cell2.txt.gz","2565","77","Non-cancer control","NA","NA","Female","Serum"
"GSM3107308","Non-cancer control [NB15070203]","GSM3107308","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107308/suppl/GSM3107308_SH6Y219_Cell1.txt.gz","2565","74","Non-cancer control","NA","NA","Male","Serum"
"GSM3107309","Non-cancer control [NB15072706]","GSM3107309","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 90","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107309/suppl/GSM3107309_SH6Y811_Cell3.txt.gz","2565","90","Non-cancer control","NA","NA","Male","Serum"
"GSM3107310","Non-cancer control [NB15111801]","GSM3107310","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107310/suppl/GSM3107310_SH6Y940_Cell3.txt.gz","2565","67","Non-cancer control","NA","NA","Female","Serum"
"GSM3107311","Non-cancer control [NB15122201]","GSM3107311","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107311/suppl/GSM3107311_SH6YG30_Cell3.txt.gz","2565","66","Non-cancer control","NA","NA","Male","Serum"
"GSM3107312","Non-cancer control [NB15122505]","GSM3107312","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107312/suppl/GSM3107312_SH6YG33_Cell4.txt.gz","2565","73","Non-cancer control","NA","NA","Female","Serum"
"GSM3107313","Non-cancer control [NB16030301]","GSM3107313","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107313/suppl/GSM3107313_SH6ZC48_Cell1.txt.gz","2565","84","Non-cancer control","NA","NA","Male","Serum"
"GSM3107314","Non-cancer control [XA0100]","GSM3107314","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107314/suppl/GSM3107314_SH5XD48_Cell2.txt.gz","2565","42","Non-cancer control","NA","NA","Female","Serum"
"GSM3107316","Non-cancer control [XA0343]","GSM3107316","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107316/suppl/GSM3107316_SH4ZQ03_Cell3.txt.gz","2565","58","Non-cancer control","NA","NA","Female","Serum"
"GSM3107318","Non-cancer control [XA0350]","GSM3107318","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107318/suppl/GSM3107318_SH4ZQ05_Cell2.txt.gz","2565","56","Non-cancer control","NA","NA","Female","Serum"
"GSM3107320","Non-cancer control [XA0471]","GSM3107320","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107320/suppl/GSM3107320_SH4ZR32_Cell2.txt.gz","2565","44","Non-cancer control","NA","NA","Female","Serum"
"GSM3107322","Non-cancer control [XA0520]","GSM3107322","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 38","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107322/suppl/GSM3107322_SH4ZR57_Cell3.txt.gz","2565","38","Non-cancer control","NA","NA","Female","Serum"
"GSM3107324","Non-cancer control [XA0557]","GSM3107324","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107324/suppl/GSM3107324_SH51D18_Cell4.txt.gz","2565","44","Non-cancer control","NA","NA","Female","Serum"
"GSM3107326","Non-cancer control [XA0644]","GSM3107326","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107326/suppl/GSM3107326_SH51E22_Cell2.txt.gz","2565","73","Non-cancer control","NA","NA","Female","Serum"
"GSM3107328","Non-cancer control [XA0647]","GSM3107328","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 53","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107328/suppl/GSM3107328_SH51E26_Cell1.txt.gz","2565","53","Non-cancer control","NA","NA","Female","Serum"
"GSM3107330","Non-cancer control [XA0685]","GSM3107330","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 41","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107330/suppl/GSM3107330_SH51E43_Cell3.txt.gz","2565","41","Non-cancer control","NA","NA","Female","Serum"
"GSM3107332","Non-cancer control [XA0716]","GSM3107332","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 59","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107332/suppl/GSM3107332_SH51E57_Cell2.txt.gz","2565","59","Non-cancer control","NA","NA","Female","Serum"
"GSM3107333","Non-cancer control [XA0743]","GSM3107333","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 57","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107333/suppl/GSM3107333_SH51G31_Cell1.txt.gz","2565","57","Non-cancer control","NA","NA","Female","Serum"
"GSM3107334","Non-cancer control [XA0965]","GSM3107334","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 51","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107334/suppl/GSM3107334_SH52P21_Cell3.txt.gz","2565","51","Non-cancer control","NA","NA","Female","Serum"
"GSM3107335","Non-cancer control [XA0995]","GSM3107335","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 53","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107335/suppl/GSM3107335_SH52615_Cell4.txt.gz","2565","53","Non-cancer control","NA","NA","Female","Serum"
"GSM3107336","Non-cancer control [XB0195]","GSM3107336","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107336/suppl/GSM3107336_SH53B25_Cell2.txt.gz","2565","68","Non-cancer control","NA","NA","Male","Serum"
"GSM3107337","Non-cancer control [XB0250]","GSM3107337","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107337/suppl/GSM3107337_SH53A66_Cell1.txt.gz","2565","69","Non-cancer control","NA","NA","Male","Serum"
"GSM3107338","Non-cancer control [XB0300]","GSM3107338","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 43","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107338/suppl/GSM3107338_SH53B13_Cell3.txt.gz","2565","43","Non-cancer control","NA","NA","Male","Serum"
"GSM3107339","Non-cancer control [XB0368]","GSM3107339","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 39","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107339/suppl/GSM3107339_SH55B09_Cell2.txt.gz","2565","39","Non-cancer control","NA","NA","Male","Serum"
"GSM3107340","Non-cancer control [XB0442]","GSM3107340","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 48","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107340/suppl/GSM3107340_SH53S22_Cell3.txt.gz","2565","48","Non-cancer control","NA","NA","Male","Serum"
"GSM3107341","Non-cancer control [XB0566]","GSM3107341","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107341/suppl/GSM3107341_SH54968_Cell1.txt.gz","2565","57","Non-cancer control","NA","NA","Male","Serum"
"GSM3107342","Non-cancer control [XB0568]","GSM3107342","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107342/suppl/GSM3107342_SH54968_Cell3.txt.gz","2565","61","Non-cancer control","NA","NA","Male","Serum"
"GSM3107343","Non-cancer control [XB0703]","GSM3107343","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107343/suppl/GSM3107343_SH55B44_Cell1.txt.gz","2565","57","Non-cancer control","NA","NA","Male","Serum"
"GSM3107344","Non-cancer control [XB0781]","GSM3107344","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 48","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107344/suppl/GSM3107344_SH55C63_Cell4.txt.gz","2565","48","Non-cancer control","NA","NA","Male","Serum"
"GSM3107345","Non-cancer control [XB0858]","GSM3107345","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107345/suppl/GSM3107345_SH56224_Cell1.txt.gz","2565","68","Non-cancer control","NA","NA","Male","Serum"
"GSM3107346","Non-cancer control [XB0930]","GSM3107346","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107346/suppl/GSM3107346_SH55M45_Cell1.txt.gz","2565","52","Non-cancer control","NA","NA","Male","Serum"
"GSM3107347","Non-cancer control [XB0989]","GSM3107347","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 35","disease status: Non-cancer control","pathological tstage: NA","pathological grade: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107347/suppl/GSM3107347_SH55R06_Cell4.txt.gz","2565","35","Non-cancer control","NA","NA","Male","Serum"
"GSM3107348","Breast Cancer [BC1056]","GSM3107348","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 64","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107348/suppl/GSM3107348_SH4YL43_Cell4.txt.gz","2565","64","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107349","Breast Cancer [BC1057]","GSM3107349","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 53","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107349/suppl/GSM3107349_SH4YL44_Cell1.txt.gz","2565","53","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107350","Breast Cancer [BC1068]","GSM3107350","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 52","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107350/suppl/GSM3107350_SH4YL44_Cell2.txt.gz","2565","52","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107351","Breast Cancer [BC1138]","GSM3107351","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107351/suppl/GSM3107351_SH4YL44_Cell4.txt.gz","2565","56","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107352","Breast Cancer [BC1179]","GSM3107352","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 77","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107352/suppl/GSM3107352_SH4YL45_Cell4.txt.gz","2565","77","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107353","Breast Cancer [BC1222]","GSM3107353","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 64","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107353/suppl/GSM3107353_SH4YE15_Cell1.txt.gz","2565","64","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107354","Breast Cancer [BC1248]","GSM3107354","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107354/suppl/GSM3107354_SH4YD51_Cell3.txt.gz","2565","68","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107355","Breast Cancer [BC1261]","GSM3107355","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 61","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107355/suppl/GSM3107355_SH4YD57_Cell4.txt.gz","2565","61","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107356","Breast Cancer [BC1277]","GSM3107356","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107356/suppl/GSM3107356_SH4YL51_Cell3.txt.gz","2565","56","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107357","Breast Cancer [BC1279]","GSM3107357","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107357/suppl/GSM3107357_SH4YL52_Cell1.txt.gz","2565","56","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107358","Breast Cancer [BC1280]","GSM3107358","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107358/suppl/GSM3107358_SH4YL52_Cell2.txt.gz","2565","58","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107359","Breast Cancer [BC1288]","GSM3107359","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107359/suppl/GSM3107359_SH4YL53_Cell2.txt.gz","2565","46","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107360","Breast Cancer [BC1289]","GSM3107360","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107360/suppl/GSM3107360_SH7YP23_Cell1.txt.gz","2565","73","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107361","Breast Cancer [BC1292]","GSM3107361","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107361/suppl/GSM3107361_SH4YL53_Cell4.txt.gz","2565","63","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107362","Breast Cancer [BC1293]","GSM3107362","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 47","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107362/suppl/GSM3107362_SH4YL54_Cell1.txt.gz","2565","47","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107363","Breast Cancer [BC1298]","GSM3107363","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107363/suppl/GSM3107363_SH4YL54_Cell3.txt.gz","2565","65","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107364","Breast Cancer [BC1301]","GSM3107364","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 51","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107364/suppl/GSM3107364_SH4YL55_Cell1.txt.gz","2565","51","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107365","Breast Cancer [BC1304]","GSM3107365","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107365/suppl/GSM3107365_SH4YL55_Cell2.txt.gz","2565","71","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107366","Breast Cancer [BC1313]","GSM3107366","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107366/suppl/GSM3107366_SH4YL55_Cell3.txt.gz","2565","44","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107367","Breast Cancer [BC1330]","GSM3107367","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 55","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107367/suppl/GSM3107367_SH4YL55_Cell4.txt.gz","2565","55","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107368","Breast Cancer [BC1331]","GSM3107368","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 43","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107368/suppl/GSM3107368_SH4YL57_Cell1.txt.gz","2565","43","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107369","Breast Cancer [BC1334]","GSM3107369","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 43","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107369/suppl/GSM3107369_SH4YL57_Cell2.txt.gz","2565","43","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107370","Breast Cancer [BC1335]","GSM3107370","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 56","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107370/suppl/GSM3107370_SH4YL57_Cell3.txt.gz","2565","56","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107371","Breast Cancer [BC1341]","GSM3107371","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 45","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107371/suppl/GSM3107371_SH4YL57_Cell4.txt.gz","2565","45","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107372","Breast Cancer [BC1345]","GSM3107372","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107372/suppl/GSM3107372_SH4YL58_Cell1.txt.gz","2565","65","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107373","Breast Cancer [BC1349]","GSM3107373","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 50","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107373/suppl/GSM3107373_SH4YL58_Cell3.txt.gz","2565","50","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107374","Breast Cancer [BC1350]","GSM3107374","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107374/suppl/GSM3107374_SH4YL58_Cell4.txt.gz","2565","44","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107375","Breast Cancer [BC1351]","GSM3107375","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107375/suppl/GSM3107375_SH4YL59_Cell1.txt.gz","2565","71","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107376","Breast Cancer [BC1352]","GSM3107376","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107376/suppl/GSM3107376_SH4YL59_Cell2.txt.gz","2565","71","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107377","Breast Cancer [BC1353]","GSM3107377","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 51","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107377/suppl/GSM3107377_SH4YL59_Cell3.txt.gz","2565","51","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107378","Breast Cancer [BC1357]","GSM3107378","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107378/suppl/GSM3107378_SH4YL59_Cell4.txt.gz","2565","42","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107379","Breast Cancer [BC1376]","GSM3107379","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 32","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107379/suppl/GSM3107379_SH4YL60_Cell2.txt.gz","2565","32","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107380","Breast Cancer [BC1410]","GSM3107380","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 47","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107380/suppl/GSM3107380_SH4YH27_Cell1.txt.gz","2565","47","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107381","Breast Cancer [BC1434]","GSM3107381","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107381/suppl/GSM3107381_SH4YL64_Cell1.txt.gz","2565","46","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107382","Breast Cancer [BC1456]","GSM3107382","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107382/suppl/GSM3107382_SH4YM07_Cell3.txt.gz","2565","67","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107383","Breast Cancer [BC1540]","GSM3107383","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 47","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107383/suppl/GSM3107383_SH4YM39_Cell4.txt.gz","2565","47","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107384","Breast Cancer [BC1552]","GSM3107384","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107384/suppl/GSM3107384_SH4YM42_Cell4.txt.gz","2565","62","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107385","Breast Cancer [BC1581]","GSM3107385","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 38","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107385/suppl/GSM3107385_SH4YL63_Cell3.txt.gz","2565","38","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107386","Breast Cancer [BC1596]","GSM3107386","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 72","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107386/suppl/GSM3107386_SH4YL63_Cell4.txt.gz","2565","72","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107387","Breast Cancer [BC1607]","GSM3107387","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Breast Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107387/suppl/GSM3107387_SH4YJ33_Cell2.txt.gz","2565","62","Breast Cancer","uncertain","uncertain","Female","Serum"
"GSM3107388","Biliary Tract Cancer [BT0045]","GSM3107388","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107388/suppl/GSM3107388_SH56B03_Cell1.txt.gz","2565","73","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107389","Biliary Tract Cancer [BT0048]","GSM3107389","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107389/suppl/GSM3107389_SH56B03_Cell4.txt.gz","2565","64","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107390","Biliary Tract Cancer [BT0052]","GSM3107390","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107390/suppl/GSM3107390_SH56H07_Cell1.txt.gz","2565","70","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107391","Biliary Tract Cancer [BT0082]","GSM3107391","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107391/suppl/GSM3107391_SH56B12_Cell2.txt.gz","2565","59","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107392","Biliary Tract Cancer [BT0096]","GSM3107392","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107392/suppl/GSM3107392_SH56B15_Cell4.txt.gz","2565","74","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107393","Biliary Tract Cancer [BT0098]","GSM3107393","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107393/suppl/GSM3107393_SH56B16_Cell2.txt.gz","2565","71","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107394","Biliary Tract Cancer [BT0113]","GSM3107394","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 75","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107394/suppl/GSM3107394_SH56B20_Cell1.txt.gz","2565","75","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107395","Biliary Tract Cancer [BT0125]","GSM3107395","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 83","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107395/suppl/GSM3107395_SH56B25_Cell1.txt.gz","2565","83","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107396","Biliary Tract Cancer [BT0142]","GSM3107396","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107396/suppl/GSM3107396_SH56B30_Cell2.txt.gz","2565","70","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107397","Biliary Tract Cancer [BT0149]","GSM3107397","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107397/suppl/GSM3107397_SH56B32_Cell1.txt.gz","2565","77","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107398","Biliary Tract Cancer [BT0184]","GSM3107398","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107398/suppl/GSM3107398_SH56B41_Cell4.txt.gz","2565","62","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107399","Biliary Tract Cancer [BT0185]","GSM3107399","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 69","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107399/suppl/GSM3107399_SH56B42_Cell1.txt.gz","2565","69","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107400","Biliary Tract Cancer [BT0186]","GSM3107400","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107400/suppl/GSM3107400_SH56B42_Cell2.txt.gz","2565","61","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107401","Biliary Tract Cancer [BT0193]","GSM3107401","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107401/suppl/GSM3107401_SH56B44_Cell1.txt.gz","2565","71","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107402","Biliary Tract Cancer [BT0194]","GSM3107402","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107402/suppl/GSM3107402_SH56B44_Cell2.txt.gz","2565","76","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107403","Biliary Tract Cancer [BT0201]","GSM3107403","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107403/suppl/GSM3107403_SH56B46_Cell1.txt.gz","2565","71","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107404","Biliary Tract Cancer [BT0210]","GSM3107404","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107404/suppl/GSM3107404_SH56B50_Cell2.txt.gz","2565","76","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107405","Biliary Tract Cancer [BT0231]","GSM3107405","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107405/suppl/GSM3107405_SH56B56_Cell3.txt.gz","2565","57","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107406","Biliary Tract Cancer [BT0235]","GSM3107406","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107406/suppl/GSM3107406_SH56B57_Cell3.txt.gz","2565","71","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107407","Biliary Tract Cancer [BT0241]","GSM3107407","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107407/suppl/GSM3107407_SH5X138_Cell2.txt.gz","2565","79","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107408","Biliary Tract Cancer [BT0247]","GSM3107408","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107408/suppl/GSM3107408_SH5X139_Cell4.txt.gz","2565","70","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107409","Biliary Tract Cancer [BT0256]","GSM3107409","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107409/suppl/GSM3107409_SH5X144_Cell1.txt.gz","2565","82","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107410","Biliary Tract Cancer [BT0257]","GSM3107410","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 43","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107410/suppl/GSM3107410_SH63Q18_Cell2.txt.gz","2565","43","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107411","Biliary Tract Cancer [BT0260]","GSM3107411","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 49","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107411/suppl/GSM3107411_SH63Q19_Cell1.txt.gz","2565","49","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107412","Biliary Tract Cancer [BT0264]","GSM3107412","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 55","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107412/suppl/GSM3107412_SH63Q20_Cell1.txt.gz","2565","55","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107413","Biliary Tract Cancer [BT0273]","GSM3107413","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107413/suppl/GSM3107413_SH63Q23_Cell2.txt.gz","2565","56","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107414","Biliary Tract Cancer [BT0277]","GSM3107414","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107414/suppl/GSM3107414_SH63Q24_Cell2.txt.gz","2565","64","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107415","Biliary Tract Cancer [BT0278]","GSM3107415","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107415/suppl/GSM3107415_SH63Q24_Cell3.txt.gz","2565","80","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107416","Biliary Tract Cancer [BT0297]","GSM3107416","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107416/suppl/GSM3107416_SH63Q30_Cell2.txt.gz","2565","82","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107417","Biliary Tract Cancer [BT0307]","GSM3107417","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107417/suppl/GSM3107417_SH63W55_Cell3.txt.gz","2565","70","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107418","Biliary Tract Cancer [BT0316]","GSM3107418","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107418/suppl/GSM3107418_SH63Q36_Cell1.txt.gz","2565","65","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107419","Biliary Tract Cancer [BT0324]","GSM3107419","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107419/suppl/GSM3107419_SH63Q39_Cell1.txt.gz","2565","79","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107420","Biliary Tract Cancer [BT0338]","GSM3107420","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107420/suppl/GSM3107420_SH63Q42_Cell3.txt.gz","2565","63","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107421","Biliary Tract Cancer [BT0353]","GSM3107421","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107421/suppl/GSM3107421_SH63Q48_Cell2.txt.gz","2565","65","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107422","Biliary Tract Cancer [BT0376]","GSM3107422","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107422/suppl/GSM3107422_SH63Q55_Cell1.txt.gz","2565","64","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107423","Biliary Tract Cancer [BT0382]","GSM3107423","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107423/suppl/GSM3107423_SH63Q57_Cell3.txt.gz","2565","66","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107424","Biliary Tract Cancer [BT0383]","GSM3107424","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107424/suppl/GSM3107424_SH63Q57_Cell4.txt.gz","2565","78","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107425","Biliary Tract Cancer [BT0388]","GSM3107425","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 69","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107425/suppl/GSM3107425_SH63Q59_Cell1.txt.gz","2565","69","Biliary Tract Cancer","uncertain","uncertain","Female","Serum"
"GSM3107426","Biliary Tract Cancer [BT0392]","GSM3107426","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107426/suppl/GSM3107426_SH63Q60_Cell1.txt.gz","2565","76","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107427","Biliary Tract Cancer [BT0398]","GSM3107427","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Biliary Tract Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107427/suppl/GSM3107427_SH63Q61_Cell3.txt.gz","2565","66","Biliary Tract Cancer","uncertain","uncertain","Male","Serum"
"GSM3107428","Colorectal Cancer [CC0235]","GSM3107428","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107428/suppl/GSM3107428_SH52T47_Cell3.txt.gz","2565","53","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107429","Colorectal Cancer [CC0249]","GSM3107429","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107429/suppl/GSM3107429_SH52T51_Cell1.txt.gz","2565","66","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107430","Colorectal Cancer [CC0294]","GSM3107430","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107430/suppl/GSM3107430_SH52T64_Cell2.txt.gz","2565","50","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107431","Colorectal Cancer [CC0296]","GSM3107431","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107431/suppl/GSM3107431_SH52T64_Cell4.txt.gz","2565","81","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107432","Colorectal Cancer [CC0304]","GSM3107432","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107432/suppl/GSM3107432_SH4YJ38_Cell1.txt.gz","2565","72","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107433","Colorectal Cancer [CC0313]","GSM3107433","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 53","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107433/suppl/GSM3107433_SH4YJ40_Cell2.txt.gz","2565","53","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107434","Colorectal Cancer [CC0387]","GSM3107434","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107434/suppl/GSM3107434_SH4YL05_Cell4.txt.gz","2565","63","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107435","Colorectal Cancer [CC0400]","GSM3107435","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107435/suppl/GSM3107435_SH4YL10_Cell1.txt.gz","2565","63","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107436","Colorectal Cancer [CC0424]","GSM3107436","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107436/suppl/GSM3107436_SH4YL20_Cell1.txt.gz","2565","60","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107437","Colorectal Cancer [CC0435]","GSM3107437","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 79","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107437/suppl/GSM3107437_SH4YL23_Cell4.txt.gz","2565","79","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107438","Colorectal Cancer [CC0460]","GSM3107438","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107438/suppl/GSM3107438_SH4YL37_Cell1.txt.gz","2565","60","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107439","Colorectal Cancer [CC0498]","GSM3107439","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107439/suppl/GSM3107439_SH4YM60_Cell2.txt.gz","2565","53","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107440","Colorectal Cancer [CC0502]","GSM3107440","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107440/suppl/GSM3107440_SH4YM61_Cell2.txt.gz","2565","58","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107441","Colorectal Cancer [CC0530]","GSM3107441","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107441/suppl/GSM3107441_SH4YS07_Cell1.txt.gz","2565","77","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107442","Colorectal Cancer [CC0596]","GSM3107442","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107442/suppl/GSM3107442_SH52J14_Cell3.txt.gz","2565","76","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107443","Colorectal Cancer [CC0603]","GSM3107443","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107443/suppl/GSM3107443_SH52J27_Cell2.txt.gz","2565","65","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107444","Colorectal Cancer [CC0695]","GSM3107444","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107444/suppl/GSM3107444_SH53A27_Cell2.txt.gz","2565","62","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107445","Colorectal Cancer [CC0736]","GSM3107445","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107445/suppl/GSM3107445_SH56F23_Cell4.txt.gz","2565","58","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107446","Colorectal Cancer [CC0758]","GSM3107446","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 80","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107446/suppl/GSM3107446_SH56F29_Cell2.txt.gz","2565","80","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107447","Colorectal Cancer [CC0781]","GSM3107447","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 43","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107447/suppl/GSM3107447_SH56G01_Cell1.txt.gz","2565","43","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107448","Colorectal Cancer [CC0783]","GSM3107448","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107448/suppl/GSM3107448_SH56G01_Cell3.txt.gz","2565","51","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107449","Colorectal Cancer [CC0861]","GSM3107449","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 59","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107449/suppl/GSM3107449_SH56G24_Cell1.txt.gz","2565","59","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107450","Colorectal Cancer [CC0890]","GSM3107450","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107450/suppl/GSM3107450_SH56G32_Cell2.txt.gz","2565","63","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107451","Colorectal Cancer [CC0981]","GSM3107451","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107451/suppl/GSM3107451_SH57M42_Cell2.txt.gz","2565","44","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107452","Colorectal Cancer [CC1021]","GSM3107452","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107452/suppl/GSM3107452_SH56H03_Cell1.txt.gz","2565","67","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107453","Colorectal Cancer [CC1084]","GSM3107453","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 37","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107453/suppl/GSM3107453_SH56H26_Cell2.txt.gz","2565","37","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107454","Colorectal Cancer [CC1150]","GSM3107454","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107454/suppl/GSM3107454_SH5X547_Cell2.txt.gz","2565","72","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107455","Colorectal Cancer [CC1192]","GSM3107455","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 86","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107455/suppl/GSM3107455_SH5X559_Cell4.txt.gz","2565","86","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107456","Colorectal Cancer [CC1193]","GSM3107456","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107456/suppl/GSM3107456_SH5X560_Cell1.txt.gz","2565","64","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107457","Colorectal Cancer [CC1205]","GSM3107457","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107457/suppl/GSM3107457_SH5YL20_Cell3.txt.gz","2565","74","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107458","Colorectal Cancer [CC1224]","GSM3107458","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107458/suppl/GSM3107458_SH5YL26_Cell2.txt.gz","2565","62","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107459","Colorectal Cancer [CC1262]","GSM3107459","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107459/suppl/GSM3107459_SH5YL63_Cell4.txt.gz","2565","62","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107460","Colorectal Cancer [CC1273]","GSM3107460","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107460/suppl/GSM3107460_SH5YQ03_Cell3.txt.gz","2565","71","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107461","Colorectal Cancer [CC1298]","GSM3107461","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107461/suppl/GSM3107461_SH5YQ11_Cell4.txt.gz","2565","70","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107462","Colorectal Cancer [CC1314]","GSM3107462","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107462/suppl/GSM3107462_SH5YQ15_Cell4.txt.gz","2565","78","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107463","Colorectal Cancer [CC1318]","GSM3107463","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107463/suppl/GSM3107463_SH5YQ16_Cell4.txt.gz","2565","62","Colorectal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107464","Colorectal Cancer [CC1371]","GSM3107464","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107464/suppl/GSM3107464_SH5YQ34_Cell4.txt.gz","2565","53","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107465","Colorectal Cancer [CC1423]","GSM3107465","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107465/suppl/GSM3107465_SH5YQ50_Cell4.txt.gz","2565","70","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107466","Colorectal Cancer [CC1533]","GSM3107466","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107466/suppl/GSM3107466_SH5YR24_Cell2.txt.gz","2565","84","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107467","Colorectal Cancer [CC1552]","GSM3107467","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 55","disease status: Colorectal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107467/suppl/GSM3107467_SH5YR44_Cell1.txt.gz","2565","55","Colorectal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107468","Esophageal Cancer [EC0020]","GSM3107468","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107468/suppl/GSM3107468_SH56B64_Cell1.txt.gz","2565","61","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107469","Esophageal Cancer [EC0032]","GSM3107469","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107469/suppl/GSM3107469_SH56B68_Cell1.txt.gz","2565","82","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107470","Esophageal Cancer [EC0035]","GSM3107470","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107470/suppl/GSM3107470_SH56B68_Cell4.txt.gz","2565","61","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107471","Esophageal Cancer [EC0038]","GSM3107471","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107471/suppl/GSM3107471_SH56F01_Cell3.txt.gz","2565","78","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107472","Esophageal Cancer [EC0042]","GSM3107472","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107472/suppl/GSM3107472_SH56F02_Cell3.txt.gz","2565","64","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107473","Esophageal Cancer [EC0052]","GSM3107473","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107473/suppl/GSM3107473_SH56F05_Cell1.txt.gz","2565","68","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107474","Esophageal Cancer [EC0057]","GSM3107474","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107474/suppl/GSM3107474_SH56F06_Cell2.txt.gz","2565","57","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107475","Esophageal Cancer [EC0091]","GSM3107475","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107475/suppl/GSM3107475_SH56F15_Cell4.txt.gz","2565","64","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107476","Esophageal Cancer [EC0103]","GSM3107476","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107476/suppl/GSM3107476_SH56H52_Cell4.txt.gz","2565","64","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107477","Esophageal Cancer [EC0105]","GSM3107477","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107477/suppl/GSM3107477_SH56F19_Cell2.txt.gz","2565","80","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107478","Esophageal Cancer [EC0121]","GSM3107478","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107478/suppl/GSM3107478_SH57M46_Cell2.txt.gz","2565","58","Esophageal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107479","Esophageal Cancer [EC0140]","GSM3107479","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 57","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107479/suppl/GSM3107479_SH57M56_Cell1.txt.gz","2565","57","Esophageal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107480","Esophageal Cancer [EC0146]","GSM3107480","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107480/suppl/GSM3107480_SH57M58_Cell3.txt.gz","2565","84","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107481","Esophageal Cancer [EC0228]","GSM3107481","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107481/suppl/GSM3107481_SH57N15_Cell1.txt.gz","2565","79","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107482","Esophageal Cancer [EC0235]","GSM3107482","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107482/suppl/GSM3107482_SH57N17_Cell4.txt.gz","2565","66","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107483","Esophageal Cancer [EC0241]","GSM3107483","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107483/suppl/GSM3107483_SH57N21_Cell2.txt.gz","2565","69","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107484","Esophageal Cancer [EC0257]","GSM3107484","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107484/suppl/GSM3107484_SH57N26_Cell2.txt.gz","2565","60","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107485","Esophageal Cancer [EC0258]","GSM3107485","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107485/suppl/GSM3107485_SH57N26_Cell3.txt.gz","2565","61","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107486","Esophageal Cancer [EC0262]","GSM3107486","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107486/suppl/GSM3107486_SH57N28_Cell3.txt.gz","2565","52","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107487","Esophageal Cancer [EC0264]","GSM3107487","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107487/suppl/GSM3107487_SH57N29_Cell1.txt.gz","2565","57","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107488","Esophageal Cancer [EC0279]","GSM3107488","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107488/suppl/GSM3107488_SH57Y25_Cell1.txt.gz","2565","64","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107489","Esophageal Cancer [EC0289]","GSM3107489","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 83","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107489/suppl/GSM3107489_SH57P18_Cell1.txt.gz","2565","83","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107490","Esophageal Cancer [EC0292]","GSM3107490","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107490/suppl/GSM3107490_SH57P18_Cell4.txt.gz","2565","73","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107491","Esophageal Cancer [EC0311]","GSM3107491","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107491/suppl/GSM3107491_SH57P23_Cell3.txt.gz","2565","73","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107492","Esophageal Cancer [EC0320]","GSM3107492","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107492/suppl/GSM3107492_SH57P25_Cell4.txt.gz","2565","75","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107493","Esophageal Cancer [EC0421]","GSM3107493","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107493/suppl/GSM3107493_SH57P58_Cell1.txt.gz","2565","74","Esophageal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107494","Esophageal Cancer [EC0437]","GSM3107494","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107494/suppl/GSM3107494_SH57P62_Cell1.txt.gz","2565","68","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107495","Esophageal Cancer [EC0450]","GSM3107495","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107495/suppl/GSM3107495_SH57P66_Cell2.txt.gz","2565","67","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107496","Esophageal Cancer [EC0490]","GSM3107496","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107496/suppl/GSM3107496_SH57T13_Cell2.txt.gz","2565","77","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107497","Esophageal Cancer [EC0523]","GSM3107497","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107497/suppl/GSM3107497_SH57T23_Cell3.txt.gz","2565","63","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107498","Esophageal Cancer [EC0526]","GSM3107498","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107498/suppl/GSM3107498_SH57T24_Cell2.txt.gz","2565","66","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107499","Esophageal Cancer [EC0531]","GSM3107499","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107499/suppl/GSM3107499_SH57T25_Cell3.txt.gz","2565","58","Esophageal Cancer","uncertain","uncertain","Female","Serum"
"GSM3107500","Esophageal Cancer [EC0546]","GSM3107500","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107500/suppl/GSM3107500_SH57T29_Cell2.txt.gz","2565","77","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107501","Esophageal Cancer [EC0567]","GSM3107501","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107501/suppl/GSM3107501_SH57X03_Cell3.txt.gz","2565","72","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107502","Esophageal Cancer [EC0570]","GSM3107502","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107502/suppl/GSM3107502_SH57X04_Cell2.txt.gz","2565","63","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107503","Esophageal Cancer [EC0581]","GSM3107503","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107503/suppl/GSM3107503_SH57X07_Cell1.txt.gz","2565","63","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107504","Esophageal Cancer [EC0586]","GSM3107504","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107504/suppl/GSM3107504_SH57X08_Cell2.txt.gz","2565","59","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107505","Esophageal Cancer [EC0587]","GSM3107505","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107505/suppl/GSM3107505_SH57X08_Cell3.txt.gz","2565","66","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107506","Esophageal Cancer [EC0595]","GSM3107506","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107506/suppl/GSM3107506_SH57X10_Cell3.txt.gz","2565","72","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107507","Esophageal Cancer [EC0630]","GSM3107507","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Esophageal Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107507/suppl/GSM3107507_SH66103_Cell2.txt.gz","2565","74","Esophageal Cancer","uncertain","uncertain","Male","Serum"
"GSM3107508","Gastric Cancer [GC0340]","GSM3107508","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107508/suppl/GSM3107508_SH5X107_Cell1.txt.gz","2565","84","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107509","Gastric Cancer [GC0354]","GSM3107509","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 61","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107509/suppl/GSM3107509_SH5X112_Cell3.txt.gz","2565","61","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107510","Gastric Cancer [GC0373]","GSM3107510","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107510/suppl/GSM3107510_SH5X117_Cell2.txt.gz","2565","52","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107511","Gastric Cancer [GC0384]","GSM3107511","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107511/suppl/GSM3107511_SH5X120_Cell1.txt.gz","2565","72","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107512","Gastric Cancer [GC0391]","GSM3107512","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 54","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107512/suppl/GSM3107512_SH5X121_Cell4.txt.gz","2565","54","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107513","Gastric Cancer [GC0397]","GSM3107513","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107513/suppl/GSM3107513_SH5X125_Cell2.txt.gz","2565","62","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107514","Gastric Cancer [GC0415]","GSM3107514","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107514/suppl/GSM3107514_SH5X129_Cell4.txt.gz","2565","80","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107515","Gastric Cancer [GC0427]","GSM3107515","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107515/suppl/GSM3107515_SH5X132_Cell4.txt.gz","2565","63","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107516","Gastric Cancer [GC0461]","GSM3107516","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107516/suppl/GSM3107516_SH62A04_Cell3.txt.gz","2565","62","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107517","Gastric Cancer [GC0469]","GSM3107517","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107517/suppl/GSM3107517_SH62A06_Cell1.txt.gz","2565","63","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107518","Gastric Cancer [GC0509]","GSM3107518","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107518/suppl/GSM3107518_SH61C63_Cell3.txt.gz","2565","73","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107519","Gastric Cancer [GC0556]","GSM3107519","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107519/suppl/GSM3107519_SH61E12_Cell2.txt.gz","2565","78","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107520","Gastric Cancer [GC0557]","GSM3107520","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107520/suppl/GSM3107520_SH61E12_Cell3.txt.gz","2565","51","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107521","Gastric Cancer [GC0565]","GSM3107521","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107521/suppl/GSM3107521_SH61E14_Cell3.txt.gz","2565","70","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107522","Gastric Cancer [GC0602]","GSM3107522","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107522/suppl/GSM3107522_SH61E27_Cell3.txt.gz","2565","68","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107523","Gastric Cancer [GC0659]","GSM3107523","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 83","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107523/suppl/GSM3107523_SH61E45_Cell4.txt.gz","2565","83","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107524","Gastric Cancer [GC0671]","GSM3107524","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107524/suppl/GSM3107524_SH61E49_Cell4.txt.gz","2565","80","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107525","Gastric Cancer [GC0724]","GSM3107525","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107525/suppl/GSM3107525_SH61F01_Cell1.txt.gz","2565","70","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107526","Gastric Cancer [GC0746]","GSM3107526","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107526/suppl/GSM3107526_SH61F17_Cell3.txt.gz","2565","74","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107527","Gastric Cancer [GC0792]","GSM3107527","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107527/suppl/GSM3107527_SH62F32_Cell2.txt.gz","2565","80","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107528","Gastric Cancer [GC0835]","GSM3107528","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107528/suppl/GSM3107528_SH61F42_Cell4.txt.gz","2565","68","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107529","Gastric Cancer [GC0873]","GSM3107529","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107529/suppl/GSM3107529_SH61F54_Cell2.txt.gz","2565","62","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107530","Gastric Cancer [GC0902]","GSM3107530","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107530/suppl/GSM3107530_SH61F62_Cell3.txt.gz","2565","60","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107531","Gastric Cancer [GC0929]","GSM3107531","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107531/suppl/GSM3107531_SH62A10_Cell1.txt.gz","2565","65","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107532","Gastric Cancer [GC0934]","GSM3107532","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107532/suppl/GSM3107532_SH62A12_Cell2.txt.gz","2565","51","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107533","Gastric Cancer [GC0947]","GSM3107533","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107533/suppl/GSM3107533_SH62A15_Cell3.txt.gz","2565","60","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107534","Gastric Cancer [GC0958]","GSM3107534","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107534/suppl/GSM3107534_SH62A18_Cell2.txt.gz","2565","70","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107535","Gastric Cancer [GC0976]","GSM3107535","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107535/suppl/GSM3107535_SH62A22_Cell4.txt.gz","2565","64","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107536","Gastric Cancer [GC0986]","GSM3107536","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107536/suppl/GSM3107536_SH62A25_Cell2.txt.gz","2565","70","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107537","Gastric Cancer [GC1010]","GSM3107537","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 45","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107537/suppl/GSM3107537_SH62A56_Cell4.txt.gz","2565","45","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107538","Gastric Cancer [GC1092]","GSM3107538","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 42","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107538/suppl/GSM3107538_SH62F18_Cell2.txt.gz","2565","42","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107539","Gastric Cancer [GC1106]","GSM3107539","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107539/suppl/GSM3107539_SH63P41_Cell1.txt.gz","2565","63","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107540","Gastric Cancer [GC1245]","GSM3107540","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 75","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107540/suppl/GSM3107540_SH63H63_Cell2.txt.gz","2565","75","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107541","Gastric Cancer [GC1260]","GSM3107541","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107541/suppl/GSM3107541_SH63P05_Cell1.txt.gz","2565","69","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107542","Gastric Cancer [GC1333]","GSM3107542","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 57","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107542/suppl/GSM3107542_SH63P23_Cell2.txt.gz","2565","57","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107543","Gastric Cancer [GC1347]","GSM3107543","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 51","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107543/suppl/GSM3107543_SH63P27_Cell4.txt.gz","2565","51","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107544","Gastric Cancer [GC1373]","GSM3107544","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107544/suppl/GSM3107544_SH63P50_Cell3.txt.gz","2565","67","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107545","Gastric Cancer [GC1433]","GSM3107545","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 47","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107545/suppl/GSM3107545_SH63Q05_Cell3.txt.gz","2565","47","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107546","Gastric Cancer [GC1444]","GSM3107546","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 78","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107546/suppl/GSM3107546_SH63Q09_Cell2.txt.gz","2565","78","Gastric Cancer","uncertain","uncertain","Female","Serum"
"GSM3107547","Gastric Cancer [GC1447]","GSM3107547","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Gastric Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107547/suppl/GSM3107547_SH63Q11_Cell1.txt.gz","2565","62","Gastric Cancer","uncertain","uncertain","Male","Serum"
"GSM3107548","Glioma [GL0001]","GSM3107548","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107548/suppl/GSM3107548_SH6XK16_Cell1.txt.gz","2565","51","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107549","Glioma [GL0003]","GSM3107549","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 35","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107549/suppl/GSM3107549_SH6XC13_Cell2.txt.gz","2565","35","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107550","Glioma [GL0005]","GSM3107550","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 34","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107550/suppl/GSM3107550_SH6XC13_Cell4.txt.gz","2565","34","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107551","Glioma [GL0012]","GSM3107551","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107551/suppl/GSM3107551_SH6XK16_Cell4.txt.gz","2565","61","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107552","Glioma [GL0014]","GSM3107552","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 31","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107552/suppl/GSM3107552_SH6XK18_Cell2.txt.gz","2565","31","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107553","Glioma [GL0018]","GSM3107553","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107553/suppl/GSM3107553_SH6XK20_Cell2.txt.gz","2565","68","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107554","Glioma [GL0025]","GSM3107554","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 26","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107554/suppl/GSM3107554_SH6XK22_Cell4.txt.gz","2565","26","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107555","Glioma [GL0029]","GSM3107555","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107555/suppl/GSM3107555_SH6XK23_Cell4.txt.gz","2565","56","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107556","Glioma [GL0034]","GSM3107556","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 17","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107556/suppl/GSM3107556_SH6XK25_Cell4.txt.gz","2565","17","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107557","Glioma [GL0040]","GSM3107557","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 17","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107557/suppl/GSM3107557_SH6XK28_Cell2.txt.gz","2565","17","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107558","Glioma [GL0044]","GSM3107558","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 54","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107558/suppl/GSM3107558_SH6XC15_Cell1.txt.gz","2565","54","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107559","Glioma [GL0046]","GSM3107559","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 31","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107559/suppl/GSM3107559_SH6XK30_Cell2.txt.gz","2565","31","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107560","Glioma [GL0047]","GSM3107560","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 39","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107560/suppl/GSM3107560_SH6XC15_Cell3.txt.gz","2565","39","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107561","Glioma [GL0055]","GSM3107561","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 85","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107561/suppl/GSM3107561_SH6XK38_Cell1.txt.gz","2565","85","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107562","Glioma [GL0059]","GSM3107562","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107562/suppl/GSM3107562_SH6XK39_Cell1.txt.gz","2565","58","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107563","Glioma [GL0061]","GSM3107563","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107563/suppl/GSM3107563_SH6XK39_Cell3.txt.gz","2565","70","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107564","Glioma [GL0069]","GSM3107564","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 32","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107564/suppl/GSM3107564_SH6XK46_Cell3.txt.gz","2565","32","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107565","Glioma [GL0074]","GSM3107565","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 35","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107565/suppl/GSM3107565_SH6XK50_Cell4.txt.gz","2565","35","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107566","Glioma [GL0078]","GSM3107566","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107566/suppl/GSM3107566_SH6XK51_Cell4.txt.gz","2565","57","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107567","Glioma [GL0084]","GSM3107567","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 37","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107567/suppl/GSM3107567_SH6XK55_Cell1.txt.gz","2565","37","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107568","Glioma [GL0090]","GSM3107568","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107568/suppl/GSM3107568_SH6XK56_Cell3.txt.gz","2565","67","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107569","Glioma [GL0091]","GSM3107569","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107569/suppl/GSM3107569_SH6XK56_Cell4.txt.gz","2565","50","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107570","Glioma [GL0098]","GSM3107570","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107570/suppl/GSM3107570_SH6XK59_Cell3.txt.gz","2565","80","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107571","Glioma [GL0099]","GSM3107571","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107571/suppl/GSM3107571_SH6XK59_Cell4.txt.gz","2565","68","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107572","Glioma [GL0100]","GSM3107572","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107572/suppl/GSM3107572_SH6XK60_Cell1.txt.gz","2565","58","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107573","Glioma [GL0115]","GSM3107573","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 40","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107573/suppl/GSM3107573_SH6XL03_Cell3.txt.gz","2565","40","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107574","Glioma [GL0124]","GSM3107574","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 83","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107574/suppl/GSM3107574_SH6XL05_Cell4.txt.gz","2565","83","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107575","Glioma [GL0128]","GSM3107575","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 44","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107575/suppl/GSM3107575_SH6XL06_Cell4.txt.gz","2565","44","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107576","Glioma [GL0132]","GSM3107576","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107576/suppl/GSM3107576_SH6XL07_Cell4.txt.gz","2565","58","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107577","Glioma [GL0133]","GSM3107577","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107577/suppl/GSM3107577_SH6XL08_Cell1.txt.gz","2565","63","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107578","Glioma [GL0135]","GSM3107578","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107578/suppl/GSM3107578_SH6XL08_Cell3.txt.gz","2565","71","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107579","Glioma [GL0142]","GSM3107579","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107579/suppl/GSM3107579_SH6XL11_Cell1.txt.gz","2565","71","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107580","Glioma [GL0146]","GSM3107580","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 41","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107580/suppl/GSM3107580_SH6XL13_Cell1.txt.gz","2565","41","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107581","Glioma [GL0171]","GSM3107581","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107581/suppl/GSM3107581_SH6XL18_Cell2.txt.gz","2565","73","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107582","Glioma [GL0173]","GSM3107582","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107582/suppl/GSM3107582_SH6XC17_Cell4.txt.gz","2565","73","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107583","Glioma [GL0175]","GSM3107583","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107583/suppl/GSM3107583_SH6XL19_Cell1.txt.gz","2565","67","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107584","Glioma [GL0180]","GSM3107584","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 24","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107584/suppl/GSM3107584_SH6XL20_Cell2.txt.gz","2565","24","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107585","Glioma [GL0189]","GSM3107585","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107585/suppl/GSM3107585_SH6XL22_Cell2.txt.gz","2565","68","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107586","Glioma [GL0198]","GSM3107586","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107586/suppl/GSM3107586_SH6XC18_Cell3.txt.gz","2565","50","Glioma","uncertain","uncertain","Male","Serum"
"GSM3107587","Glioma [GL0221]","GSM3107587","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 48","disease status: Glioma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107587/suppl/GSM3107587_SH6XC24_Cell2.txt.gz","2565","48","Glioma","uncertain","uncertain","Female","Serum"
"GSM3107588","Hepatocellular Carcinoma [HC0054]","GSM3107588","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107588/suppl/GSM3107588_SH54N40_Cell2.txt.gz","2565","59","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107589","Hepatocellular Carcinoma [HC0057]","GSM3107589","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107589/suppl/GSM3107589_SH54N41_Cell1.txt.gz","2565","70","Hepatocellular Carcinoma","uncertain","uncertain","Female","Serum"
"GSM3107590","Hepatocellular Carcinoma [HC0065]","GSM3107590","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107590/suppl/GSM3107590_SH54N44_Cell1.txt.gz","2565","69","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107591","Hepatocellular Carcinoma [HC0070]","GSM3107591","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107591/suppl/GSM3107591_SH54N45_Cell2.txt.gz","2565","67","Hepatocellular Carcinoma","uncertain","uncertain","Female","Serum"
"GSM3107592","Hepatocellular Carcinoma [HC0076]","GSM3107592","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107592/suppl/GSM3107592_SH54N51_Cell4.txt.gz","2565","68","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107593","Hepatocellular Carcinoma [HC0084]","GSM3107593","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107593/suppl/GSM3107593_SH54N54_Cell4.txt.gz","2565","60","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107594","Hepatocellular Carcinoma [HC0092]","GSM3107594","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 75","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107594/suppl/GSM3107594_SH54N56_Cell4.txt.gz","2565","75","Hepatocellular Carcinoma","uncertain","uncertain","Female","Serum"
"GSM3107595","Hepatocellular Carcinoma [HC0101]","GSM3107595","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107595/suppl/GSM3107595_SH55T22_Cell1.txt.gz","2565","81","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107596","Hepatocellular Carcinoma [HC0103]","GSM3107596","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107596/suppl/GSM3107596_SH55T22_Cell3.txt.gz","2565","57","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107597","Hepatocellular Carcinoma [HC0107]","GSM3107597","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107597/suppl/GSM3107597_SH55T23_Cell3.txt.gz","2565","70","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107598","Hepatocellular Carcinoma [HC0112]","GSM3107598","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107598/suppl/GSM3107598_SH55T24_Cell4.txt.gz","2565","60","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107599","Hepatocellular Carcinoma [HC0118]","GSM3107599","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 72","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107599/suppl/GSM3107599_SH55T26_Cell2.txt.gz","2565","72","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107600","Hepatocellular Carcinoma [HC0120]","GSM3107600","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107600/suppl/GSM3107600_SH55T26_Cell4.txt.gz","2565","74","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107601","Hepatocellular Carcinoma [HC0130]","GSM3107601","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107601/suppl/GSM3107601_SH55T31_Cell2.txt.gz","2565","75","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107602","Hepatocellular Carcinoma [HC0133]","GSM3107602","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107602/suppl/GSM3107602_SH55T33_Cell1.txt.gz","2565","64","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107603","Hepatocellular Carcinoma [HC0138]","GSM3107603","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107603/suppl/GSM3107603_SH55T35_Cell2.txt.gz","2565","66","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107604","Hepatocellular Carcinoma [HC0147]","GSM3107604","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107604/suppl/GSM3107604_SH55T37_Cell3.txt.gz","2565","61","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107605","Hepatocellular Carcinoma [HC0158]","GSM3107605","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 77","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107605/suppl/GSM3107605_SH55T41_Cell2.txt.gz","2565","77","Hepatocellular Carcinoma","uncertain","uncertain","Female","Serum"
"GSM3107606","Hepatocellular Carcinoma [HC0159]","GSM3107606","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107606/suppl/GSM3107606_SH55T41_Cell3.txt.gz","2565","57","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107607","Hepatocellular Carcinoma [HC0171]","GSM3107607","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107607/suppl/GSM3107607_SH56966_Cell1.txt.gz","2565","65","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107608","Hepatocellular Carcinoma [HC0178]","GSM3107608","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107608/suppl/GSM3107608_SH56967_Cell1.txt.gz","2565","66","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107609","Hepatocellular Carcinoma [HC0179]","GSM3107609","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107609/suppl/GSM3107609_SH55T53_Cell3.txt.gz","2565","75","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107610","Hepatocellular Carcinoma [HC0185]","GSM3107610","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107610/suppl/GSM3107610_SH55T57_Cell1.txt.gz","2565","65","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107611","Hepatocellular Carcinoma [HC0198]","GSM3107611","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107611/suppl/GSM3107611_SH55T63_Cell2.txt.gz","2565","73","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107612","Hepatocellular Carcinoma [HC0207]","GSM3107612","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107612/suppl/GSM3107612_SH5X145_Cell3.txt.gz","2565","56","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107613","Hepatocellular Carcinoma [HC0208]","GSM3107613","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107613/suppl/GSM3107613_SH5X145_Cell4.txt.gz","2565","58","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107614","Hepatocellular Carcinoma [HC0220]","GSM3107614","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107614/suppl/GSM3107614_SH5X152_Cell1.txt.gz","2565","63","Hepatocellular Carcinoma","uncertain","uncertain","Female","Serum"
"GSM3107615","Hepatocellular Carcinoma [HC0243]","GSM3107615","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107615/suppl/GSM3107615_SH5X501_Cell4.txt.gz","2565","69","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107616","Hepatocellular Carcinoma [HC0244]","GSM3107616","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107616/suppl/GSM3107616_SH5X504_Cell1.txt.gz","2565","76","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107617","Hepatocellular Carcinoma [HC0259]","GSM3107617","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107617/suppl/GSM3107617_SH5X509_Cell4.txt.gz","2565","77","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107618","Hepatocellular Carcinoma [HC0263]","GSM3107618","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107618/suppl/GSM3107618_SH5X510_Cell4.txt.gz","2565","67","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107619","Hepatocellular Carcinoma [HC0269]","GSM3107619","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107619/suppl/GSM3107619_SH5X512_Cell2.txt.gz","2565","81","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107620","Hepatocellular Carcinoma [HC0274]","GSM3107620","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107620/suppl/GSM3107620_SH5X513_Cell3.txt.gz","2565","69","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107621","Hepatocellular Carcinoma [HC0276]","GSM3107621","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107621/suppl/GSM3107621_SH5X514_Cell1.txt.gz","2565","67","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107622","Hepatocellular Carcinoma [HC0289]","GSM3107622","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 61","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107622/suppl/GSM3107622_SH5X518_Cell2.txt.gz","2565","61","Hepatocellular Carcinoma","uncertain","uncertain","Female","Serum"
"GSM3107623","Hepatocellular Carcinoma [HC0302]","GSM3107623","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 64","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107623/suppl/GSM3107623_SH5X522_Cell3.txt.gz","2565","64","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107624","Hepatocellular Carcinoma [HC0307]","GSM3107624","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107624/suppl/GSM3107624_SH5X523_Cell4.txt.gz","2565","71","Hepatocellular Carcinoma","uncertain","uncertain","Female","Serum"
"GSM3107625","Hepatocellular Carcinoma [HC0328]","GSM3107625","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 79","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107625/suppl/GSM3107625_SH5X529_Cell1.txt.gz","2565","79","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107626","Hepatocellular Carcinoma [HC0336]","GSM3107626","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107626/suppl/GSM3107626_SH5X531_Cell1.txt.gz","2565","66","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107627","Hepatocellular Carcinoma [HC0337]","GSM3107627","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Hepatocellular Carcinoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107627/suppl/GSM3107627_SH5X531_Cell2.txt.gz","2565","68","Hepatocellular Carcinoma","uncertain","uncertain","Male","Serum"
"GSM3107628","Lung Cancer [LK0005]","GSM3107628","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107628/suppl/GSM3107628_SH57X18_Cell4.txt.gz","2565","57","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107629","Lung Cancer [LK0024]","GSM3107629","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107629/suppl/GSM3107629_SH57X23_Cell3.txt.gz","2565","70","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107630","Lung Cancer [LK0102]","GSM3107630","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107630/suppl/GSM3107630_SH57X58_Cell1.txt.gz","2565","60","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107631","Lung Cancer [LK0108]","GSM3107631","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107631/suppl/GSM3107631_SH57X59_Cell3.txt.gz","2565","74","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107632","Lung Cancer [LK0109]","GSM3107632","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107632/suppl/GSM3107632_SH57X59_Cell4.txt.gz","2565","67","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107633","Lung Cancer [LK0118]","GSM3107633","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 64","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107633/suppl/GSM3107633_SH57X64_Cell1.txt.gz","2565","64","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107634","Lung Cancer [LK0120]","GSM3107634","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 59","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107634/suppl/GSM3107634_SH57X64_Cell3.txt.gz","2565","59","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107635","Lung Cancer [LK0190]","GSM3107635","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 59","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107635/suppl/GSM3107635_SH57Y23_Cell4.txt.gz","2565","59","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107636","Lung Cancer [LK0201]","GSM3107636","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107636/suppl/GSM3107636_SH59Q23_Cell3.txt.gz","2565","52","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107637","Lung Cancer [LK0209]","GSM3107637","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 49","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107637/suppl/GSM3107637_SH59Q27_Cell3.txt.gz","2565","49","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107638","Lung Cancer [LK0247]","GSM3107638","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107638/suppl/GSM3107638_SH59Q40_Cell3.txt.gz","2565","58","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107639","Lung Cancer [LK0259]","GSM3107639","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107639/suppl/GSM3107639_SH59Q44_Cell3.txt.gz","2565","63","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107640","Lung Cancer [LK0304]","GSM3107640","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107640/suppl/GSM3107640_SH57Y56_Cell2.txt.gz","2565","60","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107641","Lung Cancer [LK0347]","GSM3107641","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107641/suppl/GSM3107641_SH58L09_Cell1.txt.gz","2565","70","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107642","Lung Cancer [LK0452]","GSM3107642","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 49","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107642/suppl/GSM3107642_SH59F25_Cell2.txt.gz","2565","49","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107643","Lung Cancer [LK0466]","GSM3107643","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107643/suppl/GSM3107643_SH59F28_Cell4.txt.gz","2565","74","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107644","Lung Cancer [LK0508]","GSM3107644","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107644/suppl/GSM3107644_SH59H09_Cell2.txt.gz","2565","67","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107645","Lung Cancer [LK0523]","GSM3107645","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107645/suppl/GSM3107645_SH59H16_Cell1.txt.gz","2565","67","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107646","Lung Cancer [LK0531]","GSM3107646","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107646/suppl/GSM3107646_SH59H18_Cell1.txt.gz","2565","62","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107647","Lung Cancer [LK0534]","GSM3107647","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107647/suppl/GSM3107647_SH59H18_Cell4.txt.gz","2565","81","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107648","Lung Cancer [LK0558]","GSM3107648","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107648/suppl/GSM3107648_SH59H25_Cell4.txt.gz","2565","58","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107649","Lung Cancer [LK0600]","GSM3107649","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107649/suppl/GSM3107649_SH59H37_Cell2.txt.gz","2565","70","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107650","Lung Cancer [LK0674]","GSM3107650","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107650/suppl/GSM3107650_SH59H60_Cell4.txt.gz","2565","63","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107651","Lung Cancer [LK0688]","GSM3107651","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 50","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107651/suppl/GSM3107651_SH59H65_Cell2.txt.gz","2565","50","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107652","Lung Cancer [LK0878]","GSM3107652","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107652/suppl/GSM3107652_SH5YS49_Cell4.txt.gz","2565","42","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107653","Lung Cancer [LK0949]","GSM3107653","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 76","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107653/suppl/GSM3107653_SH5YY09_Cell3.txt.gz","2565","76","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107654","Lung Cancer [LK1042]","GSM3107654","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107654/suppl/GSM3107654_SH5YY37_Cell4.txt.gz","2565","71","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107655","Lung Cancer [LK1054]","GSM3107655","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107655/suppl/GSM3107655_SH5YY40_Cell4.txt.gz","2565","74","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107656","Lung Cancer [LK1069]","GSM3107656","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107656/suppl/GSM3107656_SH5YY45_Cell3.txt.gz","2565","66","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107657","Lung Cancer [LK1103]","GSM3107657","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 54","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107657/suppl/GSM3107657_SH5Z104_Cell1.txt.gz","2565","54","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107658","Lung Cancer [LK1154]","GSM3107658","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107658/suppl/GSM3107658_SH5Z125_Cell4.txt.gz","2565","75","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107659","Lung Cancer [LK1233]","GSM3107659","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107659/suppl/GSM3107659_SH5Z235_Cell3.txt.gz","2565","65","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107660","Lung Cancer [LK1250]","GSM3107660","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107660/suppl/GSM3107660_SH5Z241_Cell4.txt.gz","2565","61","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107661","Lung Cancer [LK1265]","GSM3107661","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 64","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107661/suppl/GSM3107661_SH5Z246_Cell3.txt.gz","2565","64","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107662","Lung Cancer [LK1407]","GSM3107662","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107662/suppl/GSM3107662_SH61602_Cell4.txt.gz","2565","68","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107663","Lung Cancer [LK1543]","GSM3107663","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107663/suppl/GSM3107663_SH61850_Cell4.txt.gz","2565","68","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107664","Lung Cancer [LK1564]","GSM3107664","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107664/suppl/GSM3107664_SH61860_Cell1.txt.gz","2565","62","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107665","Lung Cancer [LK1606]","GSM3107665","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107665/suppl/GSM3107665_SH61C08_Cell3.txt.gz","2565","70","Lung Cancer","uncertain","uncertain","Female","Serum"
"GSM3107666","Lung Cancer [LK1615]","GSM3107666","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107666/suppl/GSM3107666_SH61C11_Cell4.txt.gz","2565","71","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107667","Lung Cancer [LK1634]","GSM3107667","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Lung Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107667/suppl/GSM3107667_SH61C16_Cell3.txt.gz","2565","61","Lung Cancer","uncertain","uncertain","Male","Serum"
"GSM3107668","Ovarian Cancer [OV0075]","GSM3107668","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 38","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107668/suppl/GSM3107668_SH56H64_Cell3.txt.gz","2565","38","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107669","Ovarian Cancer [OV0081]","GSM3107669","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 41","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107669/suppl/GSM3107669_SH56H66_Cell1.txt.gz","2565","41","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107670","Ovarian Cancer [OV0083]","GSM3107670","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107670/suppl/GSM3107670_SH56H66_Cell3.txt.gz","2565","46","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107671","Ovarian Cancer [OV0090]","GSM3107671","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 58","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107671/suppl/GSM3107671_SH56H68_Cell2.txt.gz","2565","58","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107672","Ovarian Cancer [OV0102]","GSM3107672","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 51","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107672/suppl/GSM3107672_SH56J03_Cell2.txt.gz","2565","51","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107673","Ovarian Cancer [OV0106]","GSM3107673","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107673/suppl/GSM3107673_SH56J05_Cell2.txt.gz","2565","42","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107674","Ovarian Cancer [OV0114]","GSM3107674","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107674/suppl/GSM3107674_SH56J08_Cell2.txt.gz","2565","60","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107675","Ovarian Cancer [OV0121]","GSM3107675","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 64","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107675/suppl/GSM3107675_SH57G57_Cell1.txt.gz","2565","64","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107676","Ovarian Cancer [OV0123]","GSM3107676","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 48","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107676/suppl/GSM3107676_SH57G57_Cell3.txt.gz","2565","48","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107677","Ovarian Cancer [OV0135]","GSM3107677","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107677/suppl/GSM3107677_SH57G60_Cell3.txt.gz","2565","60","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107678","Ovarian Cancer [OV0140]","GSM3107678","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 61","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107678/suppl/GSM3107678_SH57G62_Cell4.txt.gz","2565","61","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107679","Ovarian Cancer [OV0145]","GSM3107679","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 41","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107679/suppl/GSM3107679_SH57G64_Cell1.txt.gz","2565","41","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107680","Ovarian Cancer [OV0152]","GSM3107680","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 54","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107680/suppl/GSM3107680_SH57G65_Cell4.txt.gz","2565","54","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107681","Ovarian Cancer [OV0158]","GSM3107681","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 64","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107681/suppl/GSM3107681_SH57G67_Cell2.txt.gz","2565","64","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107682","Ovarian Cancer [OV0161]","GSM3107682","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 60","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107682/suppl/GSM3107682_SH57G68_Cell1.txt.gz","2565","60","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107683","Ovarian Cancer [OV0168]","GSM3107683","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107683/suppl/GSM3107683_SH57M02_Cell4.txt.gz","2565","73","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107684","Ovarian Cancer [OV0170]","GSM3107684","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 41","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107684/suppl/GSM3107684_SH57M03_Cell2.txt.gz","2565","41","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107685","Ovarian Cancer [OV0176]","GSM3107685","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 35","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107685/suppl/GSM3107685_SH57M04_Cell4.txt.gz","2565","35","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107686","Ovarian Cancer [OV0181]","GSM3107686","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 79","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107686/suppl/GSM3107686_SH57M06_Cell1.txt.gz","2565","79","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107687","Ovarian Cancer [OV0198]","GSM3107687","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107687/suppl/GSM3107687_SH57M15_Cell1.txt.gz","2565","46","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107688","Ovarian Cancer [OV0211]","GSM3107688","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 81","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107688/suppl/GSM3107688_SH57M18_Cell2.txt.gz","2565","81","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107689","Ovarian Cancer [OV0222]","GSM3107689","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107689/suppl/GSM3107689_SH57M21_Cell1.txt.gz","2565","62","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107690","Ovarian Cancer [OV0225]","GSM3107690","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107690/suppl/GSM3107690_SH57M21_Cell4.txt.gz","2565","46","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107691","Ovarian Cancer [OV0254]","GSM3107691","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 31","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107691/suppl/GSM3107691_SH57M30_Cell1.txt.gz","2565","31","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107692","Ovarian Cancer [OV0262]","GSM3107692","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107692/suppl/GSM3107692_SH67R49_Cell4.txt.gz","2565","73","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107693","Ovarian Cancer [OV0269]","GSM3107693","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 61","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107693/suppl/GSM3107693_SH67R51_Cell3.txt.gz","2565","61","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107694","Ovarian Cancer [OV0295]","GSM3107694","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107694/suppl/GSM3107694_SH67R59_Cell1.txt.gz","2565","46","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107695","Ovarian Cancer [OV0304]","GSM3107695","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 44","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107695/suppl/GSM3107695_SH67R61_Cell2.txt.gz","2565","44","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107696","Ovarian Cancer [OV0320]","GSM3107696","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 72","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107696/suppl/GSM3107696_SH67S02_Cell2.txt.gz","2565","72","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107697","Ovarian Cancer [OV0324]","GSM3107697","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107697/suppl/GSM3107697_SH67S03_Cell2.txt.gz","2565","46","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107698","Ovarian Cancer [OV0332]","GSM3107698","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107698/suppl/GSM3107698_SH67S05_Cell2.txt.gz","2565","71","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107699","Ovarian Cancer [OV0346]","GSM3107699","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 47","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107699/suppl/GSM3107699_SH67S09_Cell4.txt.gz","2565","47","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107700","Ovarian Cancer [OV0350]","GSM3107700","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 55","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107700/suppl/GSM3107700_SH67S11_Cell4.txt.gz","2565","55","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107701","Ovarian Cancer [OV0395]","GSM3107701","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 34","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107701/suppl/GSM3107701_SH67S26_Cell1.txt.gz","2565","34","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107702","Ovarian Cancer [OV0399]","GSM3107702","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 49","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107702/suppl/GSM3107702_SH67S27_Cell1.txt.gz","2565","49","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107703","Ovarian Cancer [OV0402]","GSM3107703","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107703/suppl/GSM3107703_SH67S27_Cell4.txt.gz","2565","67","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107704","Ovarian Cancer [OV0410]","GSM3107704","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 59","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107704/suppl/GSM3107704_SH67S29_Cell4.txt.gz","2565","59","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107705","Ovarian Cancer [OV0411]","GSM3107705","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 50","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107705/suppl/GSM3107705_SH67S30_Cell1.txt.gz","2565","50","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107706","Ovarian Cancer [OV0430]","GSM3107706","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107706/suppl/GSM3107706_SH67S37_Cell4.txt.gz","2565","42","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107707","Ovarian Cancer [OV0440]","GSM3107707","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Ovarian Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107707/suppl/GSM3107707_SH67S40_Cell2.txt.gz","2565","62","Ovarian Cancer","uncertain","uncertain","Female","Serum"
"GSM3107708","Pancreatic Cancer [PC0235]","GSM3107708","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 44","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107708/suppl/GSM3107708_SH51W02_Cell1.txt.gz","2565","44","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107709","Pancreatic Cancer [PC0256]","GSM3107709","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107709/suppl/GSM3107709_SH51W10_Cell2.txt.gz","2565","65","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107710","Pancreatic Cancer [PC0265]","GSM3107710","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107710/suppl/GSM3107710_SH51W13_Cell3.txt.gz","2565","61","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107711","Pancreatic Cancer [PC0271]","GSM3107711","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107711/suppl/GSM3107711_SH51W15_Cell1.txt.gz","2565","59","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107712","Pancreatic Cancer [PC0273]","GSM3107712","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107712/suppl/GSM3107712_SH51W15_Cell3.txt.gz","2565","66","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107713","Pancreatic Cancer [PC0275]","GSM3107713","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107713/suppl/GSM3107713_SH51W20_Cell1.txt.gz","2565","63","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107714","Pancreatic Cancer [PC0286]","GSM3107714","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 73","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107714/suppl/GSM3107714_SH51W23_Cell4.txt.gz","2565","73","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107715","Pancreatic Cancer [PC0309]","GSM3107715","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 66","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107715/suppl/GSM3107715_SH54G28_Cell3.txt.gz","2565","66","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107716","Pancreatic Cancer [PC0331]","GSM3107716","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107716/suppl/GSM3107716_SH54G34_Cell1.txt.gz","2565","70","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107717","Pancreatic Cancer [PC0348]","GSM3107717","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 41","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107717/suppl/GSM3107717_SH54G39_Cell2.txt.gz","2565","41","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107718","Pancreatic Cancer [PC0366]","GSM3107718","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107718/suppl/GSM3107718_SH54G43_Cell4.txt.gz","2565","84","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107719","Pancreatic Cancer [PC0393]","GSM3107719","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 74","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107719/suppl/GSM3107719_SH54G54_Cell3.txt.gz","2565","74","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107720","Pancreatic Cancer [PC0445]","GSM3107720","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107720/suppl/GSM3107720_SH54N17_Cell4.txt.gz","2565","56","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107721","Pancreatic Cancer [PC0470]","GSM3107721","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107721/suppl/GSM3107721_SH54L16_Cell4.txt.gz","2565","56","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107722","Pancreatic Cancer [PC0475]","GSM3107722","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107722/suppl/GSM3107722_SH54L19_Cell1.txt.gz","2565","71","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107723","Pancreatic Cancer [PC0478]","GSM3107723","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107723/suppl/GSM3107723_SH54L19_Cell4.txt.gz","2565","63","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107724","Pancreatic Cancer [PC0483]","GSM3107724","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107724/suppl/GSM3107724_SH54L21_Cell1.txt.gz","2565","65","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107725","Pancreatic Cancer [PC0525]","GSM3107725","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107725/suppl/GSM3107725_SH54L31_Cell3.txt.gz","2565","62","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107726","Pancreatic Cancer [PC0535]","GSM3107726","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 68","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107726/suppl/GSM3107726_SH54L37_Cell1.txt.gz","2565","68","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107727","Pancreatic Cancer [PC0545]","GSM3107727","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107727/suppl/GSM3107727_SH54L45_Cell3.txt.gz","2565","76","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107728","Pancreatic Cancer [PC0551]","GSM3107728","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 70","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107728/suppl/GSM3107728_SH54L48_Cell1.txt.gz","2565","70","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107729","Pancreatic Cancer [PC0555]","GSM3107729","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 53","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107729/suppl/GSM3107729_SH54L49_Cell1.txt.gz","2565","53","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107730","Pancreatic Cancer [PC0567]","GSM3107730","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107730/suppl/GSM3107730_SH54L54_Cell1.txt.gz","2565","68","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107731","Pancreatic Cancer [PC0583]","GSM3107731","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 67","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107731/suppl/GSM3107731_SH54L58_Cell1.txt.gz","2565","67","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107732","Pancreatic Cancer [PC0593]","GSM3107732","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 57","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107732/suppl/GSM3107732_SH54L60_Cell3.txt.gz","2565","57","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107733","Pancreatic Cancer [PC0604]","GSM3107733","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107733/suppl/GSM3107733_SH54L65_Cell2.txt.gz","2565","63","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107734","Pancreatic Cancer [PC0618]","GSM3107734","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107734/suppl/GSM3107734_SH54N22_Cell4.txt.gz","2565","58","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107735","Pancreatic Cancer [PC0620]","GSM3107735","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 52","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107735/suppl/GSM3107735_SH54N05_Cell2.txt.gz","2565","52","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107736","Pancreatic Cancer [PC0663]","GSM3107736","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 79","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107736/suppl/GSM3107736_SH56843_Cell2.txt.gz","2565","79","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107737","Pancreatic Cancer [PC0675]","GSM3107737","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107737/suppl/GSM3107737_SH56847_Cell2.txt.gz","2565","51","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107738","Pancreatic Cancer [PC0696]","GSM3107738","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107738/suppl/GSM3107738_SH56852_Cell3.txt.gz","2565","65","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107739","Pancreatic Cancer [PC0728]","GSM3107739","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107739/suppl/GSM3107739_SH56947_Cell1.txt.gz","2565","63","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107740","Pancreatic Cancer [PC0734]","GSM3107740","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 70","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107740/suppl/GSM3107740_SH56863_Cell1.txt.gz","2565","70","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107741","Pancreatic Cancer [PC0753]","GSM3107741","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107741/suppl/GSM3107741_SH56868_Cell4.txt.gz","2565","71","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107742","Pancreatic Cancer [PC0768]","GSM3107742","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107742/suppl/GSM3107742_SH56905_Cell3.txt.gz","2565","74","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107743","Pancreatic Cancer [PC0770]","GSM3107743","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107743/suppl/GSM3107743_SH56949_Cell1.txt.gz","2565","63","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107744","Pancreatic Cancer [PC0821]","GSM3107744","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 71","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107744/suppl/GSM3107744_SH53S42_Cell4.txt.gz","2565","71","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107745","Pancreatic Cancer [PC0830]","GSM3107745","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 42","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107745/suppl/GSM3107745_SH54825_Cell1.txt.gz","2565","42","Pancreatic Cancer","uncertain","uncertain","Female","Serum"
"GSM3107746","Pancreatic Cancer [PC0847]","GSM3107746","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107746/suppl/GSM3107746_SH56936_Cell2.txt.gz","2565","62","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107747","Pancreatic Cancer [PC0853]","GSM3107747","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 81","disease status: Pancreatic Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107747/suppl/GSM3107747_SH56937_Cell4.txt.gz","2565","81","Pancreatic Cancer","uncertain","uncertain","Male","Serum"
"GSM3107748","Prostate Cancer [PR0279]","GSM3107748","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107748/suppl/GSM3107748_SH66222_Cell3.txt.gz","2565","73","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107749","Prostate Cancer [PR0322]","GSM3107749","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107749/suppl/GSM3107749_SH66637_Cell4.txt.gz","2565","65","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107750","Prostate Cancer [PR0327]","GSM3107750","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 80","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107750/suppl/GSM3107750_SH66639_Cell1.txt.gz","2565","80","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107751","Prostate Cancer [PR0330]","GSM3107751","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107751/suppl/GSM3107751_SH66639_Cell4.txt.gz","2565","73","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107752","Prostate Cancer [PR0369]","GSM3107752","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107752/suppl/GSM3107752_SH66650_Cell3.txt.gz","2565","65","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107753","Prostate Cancer [PR0410]","GSM3107753","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107753/suppl/GSM3107753_SH66662_Cell4.txt.gz","2565","69","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107754","Prostate Cancer [PR0433]","GSM3107754","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 82","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107754/suppl/GSM3107754_SH66707_Cell3.txt.gz","2565","82","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107755","Prostate Cancer [PR0449]","GSM3107755","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107755/suppl/GSM3107755_SH66712_Cell3.txt.gz","2565","62","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107756","Prostate Cancer [PR0463]","GSM3107756","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107756/suppl/GSM3107756_SH66717_Cell1.txt.gz","2565","77","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107757","Prostate Cancer [PR0485]","GSM3107757","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107757/suppl/GSM3107757_SH66722_Cell3.txt.gz","2565","66","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107758","Prostate Cancer [PR0495]","GSM3107758","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 84","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107758/suppl/GSM3107758_SH66727_Cell1.txt.gz","2565","84","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107759","Prostate Cancer [PR0499]","GSM3107759","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107759/suppl/GSM3107759_SH66729_Cell1.txt.gz","2565","67","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107760","Prostate Cancer [PR0530]","GSM3107760","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107760/suppl/GSM3107760_SH66736_Cell4.txt.gz","2565","62","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107761","Prostate Cancer [PR0566]","GSM3107761","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107761/suppl/GSM3107761_SH66746_Cell4.txt.gz","2565","74","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107762","Prostate Cancer [PR0589]","GSM3107762","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107762/suppl/GSM3107762_SH66752_Cell4.txt.gz","2565","62","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107763","Prostate Cancer [PR0595]","GSM3107763","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107763/suppl/GSM3107763_SH66755_Cell2.txt.gz","2565","75","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107764","Prostate Cancer [PR0604]","GSM3107764","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107764/suppl/GSM3107764_SH66757_Cell3.txt.gz","2565","62","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107765","Prostate Cancer [PR0612]","GSM3107765","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 66","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107765/suppl/GSM3107765_SH66759_Cell3.txt.gz","2565","66","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107766","Prostate Cancer [PR0630]","GSM3107766","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107766/suppl/GSM3107766_SH66802_Cell1.txt.gz","2565","65","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107767","Prostate Cancer [PR0640]","GSM3107767","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107767/suppl/GSM3107767_SH66804_Cell3.txt.gz","2565","62","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107768","Prostate Cancer [PR0641]","GSM3107768","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107768/suppl/GSM3107768_SH66804_Cell4.txt.gz","2565","71","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107769","Prostate Cancer [PR0650]","GSM3107769","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 63","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107769/suppl/GSM3107769_SH66807_Cell1.txt.gz","2565","63","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107770","Prostate Cancer [PR0662]","GSM3107770","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 55","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107770/suppl/GSM3107770_SH66932_Cell3.txt.gz","2565","55","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107771","Prostate Cancer [PR0672]","GSM3107771","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107771/suppl/GSM3107771_SH66933_Cell1.txt.gz","2565","60","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107772","Prostate Cancer [PR0724]","GSM3107772","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107772/suppl/GSM3107772_SH66836_Cell3.txt.gz","2565","71","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107773","Prostate Cancer [PR0730]","GSM3107773","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 53","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107773/suppl/GSM3107773_SH66840_Cell1.txt.gz","2565","53","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107774","Prostate Cancer [PR0760]","GSM3107774","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107774/suppl/GSM3107774_SH66848_Cell3.txt.gz","2565","69","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107775","Prostate Cancer [PR0782]","GSM3107775","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 71","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107775/suppl/GSM3107775_SH66854_Cell1.txt.gz","2565","71","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107776","Prostate Cancer [PR0794]","GSM3107776","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107776/suppl/GSM3107776_SH66857_Cell1.txt.gz","2565","59","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107777","Prostate Cancer [PR0828]","GSM3107777","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107777/suppl/GSM3107777_SH66904_Cell3.txt.gz","2565","69","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107778","Prostate Cancer [PR0840]","GSM3107778","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 74","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107778/suppl/GSM3107778_SH66907_Cell3.txt.gz","2565","74","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107779","Prostate Cancer [PR0849]","GSM3107779","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107779/suppl/GSM3107779_SH66909_Cell4.txt.gz","2565","62","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107780","Prostate Cancer [PR0879]","GSM3107780","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 67","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107780/suppl/GSM3107780_SH66917_Cell2.txt.gz","2565","67","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107781","Prostate Cancer [PR0909]","GSM3107781","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 76","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107781/suppl/GSM3107781_SH66924_Cell4.txt.gz","2565","76","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107782","Prostate Cancer [PR0951]","GSM3107782","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 73","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107782/suppl/GSM3107782_SH66940_Cell2.txt.gz","2565","73","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107783","Prostate Cancer [PR0966]","GSM3107783","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 44","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107783/suppl/GSM3107783_SH66944_Cell1.txt.gz","2565","44","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107784","Prostate Cancer [PR0984]","GSM3107784","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 62","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107784/suppl/GSM3107784_SH66955_Cell1.txt.gz","2565","62","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107785","Prostate Cancer [PR0993]","GSM3107785","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 75","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107785/suppl/GSM3107785_SH66957_Cell2.txt.gz","2565","75","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107786","Prostate Cancer [PR0994]","GSM3107786","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107786/suppl/GSM3107786_SH66957_Cell3.txt.gz","2565","65","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107787","Prostate Cancer [PR1039]","GSM3107787","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 59","disease status: Prostate Cancer","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107787/suppl/GSM3107787_SH67M03_Cell4.txt.gz","2565","59","Prostate Cancer","uncertain","uncertain","Male","Serum"
"GSM3107788","Sarcoma [SA0042]","GSM3107788","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 50","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107788/suppl/GSM3107788_SH59Q50_Cell2.txt.gz","2565","50","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107789","Sarcoma [SA0048]","GSM3107789","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 49","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107789/suppl/GSM3107789_SH59Q51_Cell4.txt.gz","2565","49","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107790","Sarcoma [SA0050]","GSM3107790","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 36","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107790/suppl/GSM3107790_SH59Q52_Cell2.txt.gz","2565","36","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107791","Sarcoma [SA0060]","GSM3107791","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 92","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107791/suppl/GSM3107791_SH59Q54_Cell4.txt.gz","2565","92","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107792","Sarcoma [SA0074]","GSM3107792","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 35","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107792/suppl/GSM3107792_SH59Q59_Cell2.txt.gz","2565","35","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107793","Sarcoma [SA0094]","GSM3107793","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 51","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107793/suppl/GSM3107793_SH59Q64_Cell1.txt.gz","2565","51","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107794","Sarcoma [SA0112]","GSM3107794","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 65","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107794/suppl/GSM3107794_SH59W03_Cell4.txt.gz","2565","65","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107795","Sarcoma [SA0148]","GSM3107795","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 62","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107795/suppl/GSM3107795_SH59W11_Cell4.txt.gz","2565","62","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107796","Sarcoma [SA0184]","GSM3107796","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 63","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107796/suppl/GSM3107796_SH59W18_Cell3.txt.gz","2565","63","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107797","Sarcoma [SA0197]","GSM3107797","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 33","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107797/suppl/GSM3107797_SH59W22_Cell2.txt.gz","2565","33","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107798","Sarcoma [SA0204]","GSM3107798","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 30","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107798/suppl/GSM3107798_SH59W24_Cell1.txt.gz","2565","30","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107799","Sarcoma [SA0232]","GSM3107799","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 68","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107799/suppl/GSM3107799_SH59W30_Cell3.txt.gz","2565","68","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107800","Sarcoma [SA0237]","GSM3107800","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 61","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107800/suppl/GSM3107800_SH59W31_Cell4.txt.gz","2565","61","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107801","Sarcoma [SA0263]","GSM3107801","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 44","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107801/suppl/GSM3107801_SH59W39_Cell3.txt.gz","2565","44","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107802","Sarcoma [SA0273]","GSM3107802","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 41","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107802/suppl/GSM3107802_SH59W41_Cell3.txt.gz","2565","41","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107803","Sarcoma [SA0280]","GSM3107803","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 78","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107803/suppl/GSM3107803_SH59W43_Cell2.txt.gz","2565","78","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107804","Sarcoma [SA0287]","GSM3107804","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 69","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107804/suppl/GSM3107804_SH59W46_Cell1.txt.gz","2565","69","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107805","Sarcoma [SA0331]","GSM3107805","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107805/suppl/GSM3107805_SH59W56_Cell4.txt.gz","2565","58","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107806","Sarcoma [SA0358]","GSM3107806","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 86","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107806/suppl/GSM3107806_SH59X01_Cell2.txt.gz","2565","86","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107807","Sarcoma [SA0380]","GSM3107807","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 27","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107807/suppl/GSM3107807_SH59X06_Cell3.txt.gz","2565","27","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107808","Sarcoma [SA0456]","GSM3107808","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 40","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107808/suppl/GSM3107808_SH59X25_Cell2.txt.gz","2565","40","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107809","Sarcoma [SA0463]","GSM3107809","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 61","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107809/suppl/GSM3107809_SH59X27_Cell1.txt.gz","2565","61","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107810","Sarcoma [SA0465]","GSM3107810","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107810/suppl/GSM3107810_SH59X27_Cell3.txt.gz","2565","60","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107811","Sarcoma [SA0478]","GSM3107811","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 27","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107811/suppl/GSM3107811_SH51Z20_Cell3.txt.gz","2565","27","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107812","Sarcoma [SA0492]","GSM3107812","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 31","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107812/suppl/GSM3107812_SH51Z39_Cell1.txt.gz","2565","31","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107813","Sarcoma [SA0550]","GSM3107813","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 50","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107813/suppl/GSM3107813_SH52121_Cell3.txt.gz","2565","50","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107814","Sarcoma [SA0580]","GSM3107814","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 46","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107814/suppl/GSM3107814_SH52134_Cell1.txt.gz","2565","46","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107815","Sarcoma [SA0585]","GSM3107815","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 29","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107815/suppl/GSM3107815_SH52135_Cell2.txt.gz","2565","29","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107816","Sarcoma [SA0646]","GSM3107816","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 58","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107816/suppl/GSM3107816_SH52223_Cell3.txt.gz","2565","58","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107817","Sarcoma [SA0682]","GSM3107817","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 49","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107817/suppl/GSM3107817_SH4YE45_Cell3.txt.gz","2565","49","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107818","Sarcoma [SA0731]","GSM3107818","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 32","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107818/suppl/GSM3107818_SH4YT05_Cell2.txt.gz","2565","32","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107819","Sarcoma [SA0802]","GSM3107819","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 31","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107819/suppl/GSM3107819_SH4YT28_Cell1.txt.gz","2565","31","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107820","Sarcoma [SA0829]","GSM3107820","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 46","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107820/suppl/GSM3107820_SH4YT35_Cell3.txt.gz","2565","46","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107821","Sarcoma [SA0850]","GSM3107821","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 26","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107821/suppl/GSM3107821_SH59Q26_Cell2.txt.gz","2565","26","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107822","Sarcoma [SA0874]","GSM3107822","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 65","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107822/suppl/GSM3107822_SH51P39_Cell2.txt.gz","2565","65","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107823","Sarcoma [SA0922]","GSM3107823","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 56","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107823/suppl/GSM3107823_SH51840_Cell1.txt.gz","2565","56","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107824","Sarcoma [SA0923]","GSM3107824","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 30","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107824/suppl/GSM3107824_SH51840_Cell2.txt.gz","2565","30","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107825","Sarcoma [SA0937]","GSM3107825","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Female","age: 28","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107825/suppl/GSM3107825_SH51845_Cell4.txt.gz","2565","28","Sarcoma","uncertain","uncertain","Female","Serum"
"GSM3107826","Sarcoma [SA0939]","GSM3107826","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 60","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107826/suppl/GSM3107826_SH51846_Cell2.txt.gz","2565","60","Sarcoma","uncertain","uncertain","Male","Serum"
"GSM3107827","Sarcoma [SA0997]","GSM3107827","Public on Nov 06 2018","Apr 20 2018","Nov 06 2018","RNA","1","Serum","Homo sapiens","tissue: Serum","Sex: Male","age: 77","disease status: Sarcoma","pathological tstage: uncertain","pathological grade: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","miRNA","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Satoko,,Takizawa","satoko.takizawa.f3@mail.toray","Toray industries inc","kamakurashi","Kanagawa","248-8555","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3107nnn/GSM3107827/suppl/GSM3107827_SH51867_Cell4.txt.gz","2565","77","Sarcoma","uncertain","uncertain","Male","Serum"
